



**HAL**  
open science

## Engineered Nanomaterials for Immunomodulation: A Review

Ragini Singh, Mamta Kumawat, Himanshu Gogoi, Harishkumar Madhyastha,  
Eric Lichtfouse, Hemant Kumar Daima

► **To cite this version:**

Ragini Singh, Mamta Kumawat, Himanshu Gogoi, Harishkumar Madhyastha, Eric Lichtfouse, et al.. Engineered Nanomaterials for Immunomodulation: A Review. ACS Applied Bio Materials, 2024, 7, pp.727 - 751. 10.1021/acsabm.3c00940 . hal-04528415

**HAL Id: hal-04528415**

**<https://hal.science/hal-04528415v1>**

Submitted on 1 Apr 2024

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.


L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Public Domain

# Engineered Nanomaterials for Immunomodulation: A Review

Ragini Singh,\* Mamta Kumawat, Himanshu Gogoi, Harishkumar Madhyastha, Eric Lichtfouse, and Hemant Kumar Daima\*

<https://doi.org/10.1021/acsabm.3c00940>  
ACS Appl. Bio Mater. 2024, 7, 727–751



**ABSTRACT:** The immune system usually provides a defense against invading pathogenic microorganisms and any other particulate contaminants. Nonetheless, it has been recently reported that nanomaterials can evade the immune system and modulate immunological responses due to their unique physicochemical characteristics. Consequently, nanomaterial-based activation of immune components, i.e., neutrophils, macrophages, and other effector cells, may induce inflammation and alter the immune response. Here, it is essential to distinguish the acute and chronic modulations triggered by nanomaterials to determine the possible risks to human health. Nanomaterials size, shape, composition, surface charge, and deformability are factors controlling their uptake by immune cells and the resulting immune responses. The exterior corona of molecules adsorbed over nanomaterials surfaces also influences their immunological effects. Here, we review current nanoengineering trends for targeted immunomodulation with an emphasis on the design, safety, and potential toxicity of nanomaterials. First, we describe the characteristics of engineered nanomaterials that trigger immune responses. Then, the biocompatibility and immunotoxicity of nanoengineered particles are debated, because these factors influence applications. Finally, future nanomaterial developments in terms of surface modifications, synergistic approaches, and biomimetics are discussed.

**KEYWORDS:** Surface engineering, immunomodulation, biocompatibility, immunotoxicity, nanomedicine

## 1. INTRODUCTION

Nanomaterials are particles with size less than 100 nm and different properties compared to their bulk counterparts. With the advent of nanotechnology, a range of different nanomaterials have received profound interest, owing to their novel characteristics and potential applications. Nanomaterials exhibit distinct optical, chemical, physical, and biomedical properties, and they are being explored toward industrial, biomedical, environmental, agriculture, chemical, and military applications.<sup>1–3</sup>

In biomedical applications, nanomaterials have garnered attention by overcoming barriers like therapeutic delivery, imaging, regenerative medicine, enhancing drug solubility, targeting, and bioavailability.<sup>4–17</sup> However, a preeminent goal of biomedical nanotechnology is to engineer biocompatible products that do not induce inflammation. To accomplish this, specific nanosized particles such as liposomes, emulsions, exosomes, solid-lipid nanoparticles, dendrimers, polymers, proteins, metal/metal oxide nanoparticles, and hydrogel nanoparticles have paved the way for various applications in biomedical sciences. Moreover, the evolution of nanotechnology and engineered nanomaterials has unique immunological responses elicited by different types of nanomaterials.<sup>1,18,19</sup>

In this context, the characteristics and physicochemical properties of nanomaterials vary with the composition and

enable them to interact differently with the host immune cells upon immunization and evoke discrete responses. Moreover, nanomaterials can be selectively engineered to avoid immune recognition. Indeed, the physicochemical and surface attributes like size, morphology, surface charge, roughness, and hydrophobicity of the nanomaterials dictate the nature of interaction with immune system and play a crucial role in deciding nanomaterials fate.<sup>18,20–22</sup> Several reports have demonstrated that nanomaterials play major role in photothermal, vaccine-mediated, and antigen-specific immunotherapy.<sup>4,23,24</sup>

The immune system defends the host from various infections and aids in maintaining a tolerogenic environment in the aftermath of an inflammatory response. The immune system is composed of the innate and adaptive systems, wherein both are intertwined, resulting in an immune response. Interestingly, the immunized nanomaterials act as “intruders”, and they can directly or indirectly influence the

host immune system to persuade an immune response, which can be either immunoinflammatory or immunosuppressive.<sup>20,25,26</sup> The nanomaterials can mediate subtle or robust changes within the immune system, like affecting immune cascade pathways, modulating gene regulations, altering cellular mobility, and even regulating cellular and physiological changes.<sup>27–29</sup> In this context, potassium chloride nanoparticles have been reported to induce immunogenic cell death in cancer immunotherapy via altering the osmotic pressure and thus inducing hypotonic conditions.<sup>5</sup> Therefore, monitoring the immunomodulatory behavior of nanomaterials is extremely important for their safety assessment and biomedical implementations. While major research related to nanomaterials has focused on deliverables, the underlying mechanism of nanomaterial evoked immune response is yet to be deciphered in detail.

The immunoinflammatory properties of different types of nanomaterials have been extensively utilized in pharmaceutical applications like vaccine delivery and antitumoral therapeutics.<sup>30–32</sup> The nanomaterials-based vaccines or drug delivery have been highly successful as the most recent FDA approved therapeutic to deliver cytarabine and daunorubicin to treat acute myeloid leukemia (VYXEOS), hafnium oxide nanoparticles to treat locally advanced squamous carcinoma in the cell (NBTXR3/Hensify), and to deliver Spike-mRNA in Covid vaccines.<sup>33–40</sup> Apart from the applications, over 20 nanomaterial-based formulations are currently prescribed to treat various cancers, fungal infections, kidney diseases, and even imaging purposes.<sup>41–48</sup>

Nevertheless, nanomaterial-mediated immunostimulatory effects sometimes act as a double-edged sword, and they have been associated with diverse side-effects like hypersensitivity, inflammation, toxicity, inhibition of phagocytic ability of antigen presenting cells (APCs), and anaphylaxis.<sup>28</sup> Further, recent human and animal studies have demonstrated biological dispersal of nanomaterials in liver, heart, spleen, kidney, and brain upon oral and inhalation exposure.<sup>49</sup> Moreover, during metabolism, nanomaterials have been observed to congregate on the liver and inhaled nanomaterials in the lungs. Considering the estimated half-life of nanoparticles to be 700 days, they can result in a consistent threat to the tissues and organs.<sup>50</sup> Contemporary studies related to nanomaterial noxiousness have identified their diverse properties (i.e., particle size, surface charge, and crystallinity) in correlation with their cellular toxicity.<sup>51–56</sup> The toxicity also tends to induce structure damage to mitochondrial, depolarization of mitochondrial membrane, deoxyribonucleic acid (DNA) damage, lactate dehydrogenase (LDH) overproduction, electron transport chain impairment, alteration in gene responses involved in apoptosis, and cellular ion dysregulation.<sup>57–62</sup>

Remarkably, suppression of the immune system is desirable in numerous medical applications like (i) autoinflammation or autoimmunity, when the immune system reacts to self-antigens, (ii) organ or tissue transplant to avoid graft rejection, (iii) post pathogen infection to dampen the inflammatory response, and (iv) reduction of the inflammatory response in lieu of exposure to environmental and dietary irritants. Nanomaterial-mediated immune suppression can be categorized as either “direct immune suppression” or ‘indirect immune suppression’. In the context of indirect immune suppression, nanomaterial-mediated delivery of immunosuppressive drugs like cyclosporine, tacrolimus, and sirolimus

are under evaluation.<sup>63–68</sup> Reformulation of these drugs with nanotechnology platforms has alleviated the toxic side-effects, inferior bioavailability, and poor water solubility. Most of the studies related to immune suppression have relied on the delivery of immune-suppressive drugs using nanoparticle-based delivery vehicles, while direct immune suppression has been assessed for engineered physicochemical properties of nanomaterials to directly interact with the immune system. The engineered properties of nanomaterials can induce anti-inflammatory and immune-suppressive responses in complement to immunosuppressive drugs.

Herein, metal nanoparticles like gold, metal oxide nanoparticles like iron and cerium, and carbon-based nanomaterials like carbon nanotubes (CNTs) and fullerenes have demonstrated the potential to mount an anti-inflammatory response by the induction of immune-suppressive cytokines, transforming growth factor- $\beta$ , sequestering reactive oxygen species (ROS), generation of regulatory T cells, reduction of T helper type 1 (Th1) response, and reduction of T helper type 2 (Th2) allergic response against ovalbumin sensitization.<sup>69–71</sup> However, the same nanoparticle preparations have also been reported to induce a pro-inflammatory response.<sup>72–76</sup> Therefore, further analyses pertaining to surface characteristics, route of exposure, and experimental model need to be optimized to reach a conclusive opinion. Nevertheless, fundamental studies about nanoparticle-mediated immune-stimulatory properties have contributed to understanding and development of this important area of medicine.<sup>77–79</sup>

Realizing the importance of nanomaterial-mediated immune responses and their potential role in medicine, in this review, existing up-to-date knowledge of nanoparticle-mediated immunomodulation has been provided. Herein, in-depth discussion about the essential surface and physicochemical properties of nanomaterials, which are important to exhibit a controlled immune response, has been discussed. Moreover, attempts are made to explore the signaling pathways and to interpret the mechanism of action shown by the engineered nanoparticles. Later, the focus is on the existing setbacks associated with nanotechnology-mediated immunostimulant and immunosuppression performances. Finally, perspectives for better understanding of nanoengineering toward immunomodulation and development of target-oriented nanomaterials are suggested with experimental model analysis and potential application in nanomedicine.

## 2. THE IMMUNE SYSTEM AND NANOMATERIALS

The immune system is categorized as innate or adaptive because of the mechanism of action. The innate system has been considered a nonspecific immune response, and it destroys foreign elements upon interaction with them. The innate immune system contains neutrophils, mast cells, macrophages, and dendritic cells, and it reacts primarily by engulfing foreign particles and cytokines release. The adaptive immune system responds by specialized B cells or T cells. In the innate immune system, phagocytic cells serve as APCs and supply specific antigens to B and T cells for their degradation and removal.<sup>79</sup> Presently, various nanoparticle-based formulations exert significant impact on the immune system by explicitly interacting with immune cells and molecules. In immunized mice, nanomaterials exposure induces a high serum level of antigen-specific Immunoglobulin G (IgG) and is known to involve the complement system and toll-like receptors, or both.<sup>80,81</sup>


Even though reports show that nanoparticles may cause inflammation, this is not necessarily an indicator of toxicity. In several ways, the nanoparticles can intermingle with the immune system and may elicit inflammation due to the involvement of macrophages, neutrophils, and other effector cells. Nevertheless, it is crucial to differentiate chronic and acute inflammation to analyze their severe effect over human health.<sup>82</sup> An early and short-term response of the body to adverse stimuli is known as acute inflammation, whereas in chronic inflammation, the body transmits inflammatory cells even in the absence of an outside danger. The chronic inflammation may last for several months or years. Studies have revealed that nanoparticles can also induce inflammasome activation in macrophages, which is a multiprotein complex and serves as an innate immune system-mediated inflammatory response.<sup>83</sup> In addition, a few caspases like caspase-1, -4, -5, and -12 in humans and caspase-1, -11, and -12 in mice activate the inflammatory responses in combination to inflammasomes. Thus, studies regarding activation of “noncanonical” inflammasomes are expected to open new avenues to explain the inflammatory effect of nanomaterials. Besides, nanomaterials exposure can also upregulate the production of inflammatory cytokines via dendritic cells. Negatively charged polyethylene glycol-coated gold nanoparticles are reported to enhance production of TNF- $\alpha$  in human blood monocyte-derived dendritic cells, whereas positively charged poly(vinyl alcohol)-coated gold nanoparticles induce production of IL-1 $\beta$  in the presence of lipopolysaccharide.<sup>84</sup> However, attention has been limited regarding the inflammatory effect of such nanoparticles due to the presence of lipopolysaccharide, which is ubiquitously present as a contaminant. Various reports suggest that extreme and frequent exposure of nanomaterials can alter the gut microbiota, which, in turn, has potential to modulate the inflammatory activity and epithelium integrity of the intestine. Nanoparticle exposure reduces the short chain fatty acid (SCFA)-producing bacteria, which play an essential role in regulation of gut immunity and thus disturbing the immune homeostasis to stimulate inflammation.<sup>85</sup> Nanomaterials such as silver nanoparticles, graphene oxide, and CNTs have been reported to disrupt the gut microbiota, and they can increase the level of inflammatory cytokines IL-1 $\beta$ , IL-6, and TNF- $\alpha$  and upsurge intestinal permeability.<sup>86,87</sup> Likewise, adsorption of different biomolecules on nanoparticles may affect the plasma protein folding, and it can be recognized by immune cells to induce significant inflammatory reaction.<sup>82</sup>

On the contrary, due to the important role of macrophages in several pathogenic processes, different nanomaterials have been investigated for their interaction with macrophages. Nanomaterials decorated with ligands such as peptides or monoclonal antibodies can specifically bind to the receptors, which are overexpressed at the macrophage surface. Nanomaterials exposure to macrophages can cause monocyte mobilization, polarization modulation, bone marrow activation, and microvascular permeability enhancement. In the treatment of inflammatory diseases, nanomaterials can efficiently target various inflammatory monocyte production stages. In this context, nanomaterials loaded with corticosteroids and CCR2 siRNA have revealed bone marrow activity modulation under an inflammatory response. The nanomaterials interaction reduces monocyte accumulation at inflammation sites and suppresses occurrence of myocardial infarction, atherosclerosis, and pancreatic islet transplantation in diabetes.<sup>7,88</sup> Chronic inflammation induces mobilization of macrophages via differ-


ent chemokines like CCL2 and CCL7 and their accumulation at the site of inflammation.<sup>89,90</sup> Consequently, nanomaterials can directly affect the mobilization and localization of macrophages and thus serve as anti-inflammatory agents. Recently, zinc oxide nanoparticles have been shown to induce metabolic reconfiguration which in turn stimulates the macrophage polarization of THP-1 cells toward classical activation.<sup>91</sup>

Taking all of this into consideration, the active participation and accumulation of neutrophils in acute inflammation has been investigated postinteraction with nanoparticles. In the recent past, a range of nanomaterial formulations are reported to efficiently inhibit the migration and proliferation as well as depletion of inflammation-related neutrophils.<sup>92</sup> For example, pH-responsive doxorubicin conjugated albumin nanoparticles have been shown to target and deplete the activated neutrophils. Further, it has been indicated that nanoformulations internalized in neutrophils were cleaved in the acidic environment to release doxorubicin, which induces apoptosis in neutrophils. This can be efficiently used in acute inflammation. Nanoparticles with neutrophil membrane coatings acquire some characteristics that are similar to those of normal neutrophils. They could target inflamed cells, evade immune surveillance, and combat pathogenic molecules. For the management of inflammatory diseases, neutrophil imitating nanoparticles have consequently been considered as an essential therapeutic approach.<sup>93</sup>

In the context of above, polymeric nanomaterials coated with a neutrophil membrane are developed for treatment of rheumatoid arthritis as displayed in Figure 1.<sup>6</sup> In a collagen-induced arthritis mouse model and a human transgenic mouse



**Figure 1.** (A) Neutrophil-nanoparticles are intended to reduce joint degeneration and synovial inflammation in inflammatory arthritis. Natural human neutrophil membranes are used to encase polymeric cores to create neutrophil-nanoparticles, mimicking source cells to bind immunoregulatory molecules without amplifying immune cascades that enhance disease. (B) Binding capacity of human neutrophil-nanoparticles with (a) IL-1 $\beta$  and (b) TNF- $\alpha$ . Adapted with permission from ref 6. Copyright 2018, Nature.



**Figure 2.** (A) The treatment strategy was studied using a collagen-induced arthritis (CIA) mouse model. (B) Change in hind knee diameter from day 0 to day 60 following the CIA introduction. (C, D) Knee section of neutrophil-nanoparticles, phosphate buffer saline (PBS), anti-IL-1 $\beta$  antibody, or anti-TNF- $\alpha$  antibody-treated mice stained with hematoxylin, eosin, and safranin-O. (E) Using safranin-O-stained sections of mice from distinct treatment groups; the cartilage content was measured. (F) Pictorial representation depicting immunohistochemical staining on sections of a mouse knee treated with different groups for CD248 and fibronectin. Scale bars: 10  $\mu$ m. Adapted with permission from ref 6. Copyright 2018, Nature.

model, the advanced nanomaterials could efficiently suppress synovial inflammation, neutralize pro-inflammatory cytokines, and target deeply in the cartilage matrix to offer chondroprotection for joint damage. The neutrophil-nanoparticles were expected to resemble the source cells by showing neutrophil plasma membranes on their surface, thereby binding with immunoregulatory substances that otherwise target endogenous neutrophils (Figure 1A). The potential of human neutrophil-nanoparticle binding capacity to IL-1 and TNF is examined, which plays a key role in the onset and progression of rheumatoid arthritis. The Hill equation was used to calculate the neutrophil-nanoparticles half-maximum inhibitory concentration (IC<sub>50</sub>), which was found to be 188 and 1327 g mL<sup>-1</sup> for IL-1 and TNF, respectively, based on the measured binding kinetic profiles as shown in Figure 1B.


Additionally, employing a collagen-induced arthritis mouse model, neutrophil-nanoparticle's ability to prevent joint damage was investigated. When arthritis was induced in collagen-induced arthritis mice, the knee joints where mouse neutrophil-nanoparticles were introduced began to expand slightly, as shown in Figure 2A. As in controls, mice received injections of phosphate buffer saline (PBS), anti-IL-1 $\beta$ , or anti-TNF- $\alpha$ . The transverse knee diameter of mice given neutrophil-nanoparticles injections at the study's end point was akin to that of animals given anti-IL-1 $\beta$  or anti-TNF- $\alpha$  treatment, but much lower than the phosphate buffer saline group, indicating a decrease in cellular influx and edema formation as displayed in Figure 2B. The mice's knee joints

were also divided into sections for histological examination. The neutrophil-nanoparticles group's hematoxylin and eosin (H&E)-stained sections revealed chondrocyte's uniform distribution without any clear signs of degradation in the articular cartilage. In contrast, the control group had a significant neutrophil infiltration in the synovium and joints, and chondrocytes were largely absent. Anticytokine-treated groups displayed reduced neutrophil infiltration but mild chondrocyte hypertrophy and depletion as represented in Figure 2C. Sections stained with safranin-O revealed that the cartilage of the neutrophil-nanoparticles group had more sulfated glycosaminoglycans (sGAGs) than that of the control group, but similarly to that of the anticytokine groups (Figure 2D and E).

Besides, the fibroblast-like synoviocyte phenotype in the synovial inflammatory lining was investigated. Herein, specifically stained fibroblast-like synoviocytes for CD248 and fibronectin expression are used, since these molecules have been shown to upregulate IL-1 $\beta$  and TNF- $\alpha$ . The aggressive phenotype that enters the extracellular matrix to provoke joint destruction in rheumatoid arthritis is indicated by an elevated expression of these markers. As witnessed in Figure 2F, the neutrophil-nanoparticles group had poor CD248 staining and few positively stained cells in the synovium, but the control group's sections had a significant number of CD248-positive cells. Control group joints, neutrophil nanoparticles, and anticytokine groups' synovium did not contain any fibronectin-positive cells.

**Table 1. Different Types of Nanomaterials and Response Shown by the Immune System after Interaction with Nanomaterials**


Nanomaterials	Immune response	ref
Titanium dioxide nanoparticles	Monocyte activation, inflammation, histamine release, apoptosis and necrosis induction in macrophages, ROS production.	101
Zinc oxide nanoparticles	Induces inflammation and stimulate apoptosis via ROS production.	102
Cerium oxide nanoparticles	Anti-inflammatory effect, reduce ROS production, inhibit release of pro-inflammatory cytokines in murine macrophages, activates APCs for production of IL-10 to induce T-cell proliferation with Th2 dominance.	2
Iron oxide nanoparticles	Stimulate release of transforming growth factor- $\alpha$ , immunoglobulin E (IgE), cytokines IL-2, -12, -4, and -5, and pro-inflammatory cytokines, induction of T regulatory cell expansion, depletion of autoreactive B cells, inhibiting CD4 <sup>+</sup> T cells.	98, 103–105
Silicon dioxide (silica) nanoparticles	Macrophage polarization modulation, no inflammatory cytokines production in RAW 264.7.	106
Gold nanoparticles	Anti-inflammatory effects induce apoptosis, oxidative stress, liver inflammation, and release of IL-1 $\alpha$ , -1, -2, -4, -6, -8, and -10. Accumulate in macrophage and Kupffer cells, modulation of macrophage polarization, and depletion of autoreactive T cells.	99, 107–109
Silver nanoparticles	Induces immunotoxicity, ROS production and inflammation.	110
Carbon nanotubes	Induces immunosuppression by releasing prostaglandins, IL-10, CCL11, IL-6, interferon (IFN), IL-13 and transforming growth factor- $\beta$ , intravenous injection of multiwalled carbon nanotubes (MWCNTs) induces Th2 mediated immune response, increases the quantity of CD4 <sup>+</sup> and CD8 <sup>+</sup> T lymphocytes in mouse spleens.	111
Graphene	Induces Th2-facilitated immune response and release of IL-5, IL-13, and IL-33.	112
Quantum dots	Induces ROS generation and causes immunosuppression via reducing TNF- $\alpha$ , Kc/CXCL-1, and IL-8.	113
Lipid-based nanomaterials	Inflammatory effect, stimulation of immune response by IFN - $\alpha$ , T lymphocyte cytotoxicity, modulation of monocyte recruitment.	79, 114
Liposomes	Monocyte production inhibition, egression in bone marrow, macrophage depletion.	7, 115
PLGA nanoparticles	Reduces IL-1 $\beta$ and TNF- $\alpha$ level, neutralization of endotoxins, proinflammatory cytokines, and pathogenic cytokines.	6, 116, 117



**Figure 3.** (A) Illustration of mechanism of action for induction of the immune-suppressive environment. Gold nanoparticles, C<sub>60</sub> fullerenes, dendrimers, and PLGA nanoparticles suppress production of IL-4 and IL-12p70 cytokines limiting Th2 and Th1 CD4<sup>+</sup> T cell proliferation and induces IL-10 and transforming growth factor- $\beta$  (TGF- $\beta$ ) producing regulatory T cell. (B, C) Possible mechanism of action of suppression of the inflammatory response. C<sub>60</sub> fullerene, gold nanoparticles, and dendrimers inhibit lipopolysaccharide (LPS) mediated nuclear factor kappa (NF- $\kappa$ B) transcription, pro-inflammatory cytokines, and mitochondrial ROS production by obstructing toll-like receptor-4 pathway.

In recent times, the emphasis is on coronavirus-induced neutrophil-related inflammation and pro-inflammatory cytokine release.<sup>94,95</sup> It has been confirmed that exogenously administered DNase-1-conjugated polydopamine-poly-(ethylene glycol) nanoparticles efficiently suppress the cytokine elevation and neutrophil activity.<sup>96</sup> Treatment with

nanoformulations indicates a significant reduction in inflammatory cytokine level and neutrophil cell count, which in turn enhances the survival rate. Further, nanomaterials interact with lymphocytes to modulate immune response during inflammatory diseases treatment. It has been proven that the development of poly(lactide-co-glycolide) nanomaterials con-



**Figure 4.** (A) Schematic showing the antitumor activity of CPI-613 and 3-bromopyruvate (3-BPA) conjugated BCP nanoparticles. (B) Western blotting of TBK1 and STING in AML12 and Hepa1-6 cells. (C) STING dimerization effects in Hepa1-6 cells treated with BCP nanoparticles, amide benzimidazole (ABZI), and BCP nanoparticles + amide benzimidazole. (D) Effects of BCP nanoparticles, amide benzimidazole, and BCP nanoparticles + amide benzimidazole-treated Hepa1-6 cells-activated TBK1 in AML12 cells' phosphorylation. (E) Hepa1-6 cells and (F) Hepa1-6 cells treated with BCP nanoparticles triggered the phosphorylation of TBK1. (G) Hepa1-6 cells incubated with BCP nanoparticles show the relative production of IFN- $\beta$ . Adapted with permission from ref 133. Copyright Creative Commons Attribution 4.0 International License.

tain encapsulated antigen [PLG(Ag)] for treatment of Th2-mediated allergic airway inflammation. A specific nanoformulation can significantly suppress the ovalbumin-induced response and inflammation both prophylactically and therapeutically.<sup>97</sup> Additionally, iron oxide nanoparticles can suppress the lung inflammation induced by ovalbumin, and they can lower the production of IL-5 and IL-13, thus slowing the differentiation and expansion of CD4<sup>+</sup> T cells.<sup>98</sup>

Depletion of T lymphocytes is another important way by which nanomaterials exert anti-inflammatory effects. In one of the studies, methotrexate drug conjugated gold nanoparticles exhibited a superior anti-inflammatory effect in comparison to methotrexate alone by significantly reducing the gamma delta ( $\gamma\delta$ ) T cells, CD4<sup>+</sup> T cells, and neutrophils.<sup>99</sup> Further, it is explained that nanoformulations can significantly reduce the proliferation and keratinocyte differentiation. The engineered nanomaterials act on the immune cells directly by blocking the proliferation of T cells, apoptosis promotion, and diminishing Th1 and T helper type 17 (Th17) cytokine production. Other than this, autoreactive B cells are known to secrete autoantibodies, and they are also involved in various inflammatory diseases.<sup>100</sup> Thus, the current nanomaterial strategy majorly focuses on the depletion of autoreactive B cells to manage inflammatory conditions. Table 1 and Figure 3 show the responses of the immune system to different nanomaterials.

Beyond the cellular components, several other molecules such as cytokines (IL-1, -6, and TNF- $\alpha$ ) and enzymes (proteases and lipases) are also responsible for inflammatory conditions. Nanomaterials can affect these inflammation-related molecules either by modulating their production through altering source cells or by direct contact like neutralizing effect, absorption, energy, etc. The neutralization of endotoxins and proinflammatory cytokines in a sepsis model has been achieved by macrophage membrane-coated nanomaterials.<sup>116</sup> Various investigations have revealed the development of melanin-based nanomaterials to scavenge reactive oxygen and nitrogen species and inhibit the production of proinflammatory cytokines like IL-1 $\beta$ , and thus display an anti-inflammatory effect.<sup>118,119</sup>

On the divergent side, a few reports have suggested that exposure of nanomaterials shows no significant effect on intestinal immunity due to their rapid excretion. It has been reported that mice fed zinc oxide (ZnO) nanoparticles (1600 mg/kg chow) for 270 days straight had no detectable particle dispersion in the gastrointestinal tract. Therefore, it has been recommended that there is not a generic influence on biodistribution and accumulation; rather, it should be unique to each nanomaterial.<sup>120</sup>

### 3. NANOMATERIALS-MEDIATED ANTI-INFLAMMATORY RESPONSE AND IMMUNE SUPPRESSION


Immunosuppression can be defined as effective reduction of the immune system in response to either drug or other materials, which influences the onset and enhances disorders like cancer and autoimmune diseases. Herein, the innate immunity encompasses macrophage and neutrophil activation to secrete cytokines, thus leading to production of local inflammation. This kind of inflammation is typically followed by the adaptive immune response, which stimulates antigen specific T and B cells.<sup>121</sup>

In this context, various types of nanomaterials with engineered physicochemical assets have the potential to

modulate the immunological response. Upon interaction with biological fluids, proteins, and biomolecules, nanoparticles tend to form surface protein corona, which alters physicochemical assets of nanomaterials.<sup>122</sup> Further, the engineered properties like shape, size, surface charge, surface roughness, and surface chemistry of nanomaterials also have significant effects on the immunological responses. Regardless of the core material, the smaller the particle size is, the greater is the material's capacity to penetrate biological barriers and provoke an inflammatory reaction.<sup>123,124</sup> The engineered nanomaterials are reported to carry and locally deliver immunosuppressive agents. In addition to the above beneficial effects, the interaction between nanomaterials and the immune system can be adverse in nature if the nanomaterials are not designed with desired properties. For example, *in vitro* experiments have revealed that nanomaterials can trigger the production of ROS in lung epithelial cells and macrophages leading to possible lung injury. Thus, the properties of nanomaterials need to be viewed very carefully before proposing, and the properties must be tailored for the end applications.<sup>125,126</sup>

Immunosuppression or immunosuppressive agents can be beneficial when they promote the inhibition of inflammatory or autoimmune conditions.<sup>126</sup> Inflammation is the defense mechanism originating from infectious or physical agents, ROS, and metabolic stress. However, in certain conditions, the inflammatory processes become detrimental and lead to the progression of many prevalent conditions ranging from cardiovascular, rheumatoid arthritis, osteoarthritis, sepsis to genetic diseases.<sup>127–130</sup> Motivated from the above beliefs, various nanomaterials have been specifically engineered to regulate the pro- and anti-inflammatory responses *via* preferentially targeting the tissue from the administration site. It can be achieved due to the modulation of nanomaterials to pass through the metabolic barriers without affecting the healthy cells and tissues.<sup>131,132</sup>

Recently, 3-bromopyruvate (3-BPA) and CPI-613 conjunctively combined BCP nanoparticles are revealed to act as immune activators for effective immunotherapy-based tumor suppression as shown in Figure 4A.<sup>133</sup> The BCP nanoparticles activate the stimulator of interferon genes (STING) signal pathway and antitumor innate immunity in Hepa1–6 cells. First, Hepa1–6 cells had a significant levels of STING expression, while normal hepatocyte AML12 cells had little to no STING (Figure 4B). Following BCP nanoparticles treatment, the STING agonist amide benzimidazole (ABZI) was chosen as the positive control to identify STING dimerization in Hepa1–6 cells. The outcomes demonstrated that STING dramatically dimerized after being exposed to BCP nanoparticles for either 6 or 12 h (Figure 4C). The finding suggested that BCP nanoparticles could function as agonists to activate STING. According to previous reports, the cyclic guanosine monophosphate (GMP)–adenosine monophosphate (AMP) synthase (cGAS) enzyme will first activate cyclic guanosine monophosphate–adenosine monophosphate (cGAMP) before activating STING and producing type-I interferon and proinflammatory cytokines. Here, it has been assumed that the BCP treatment of Hepa1–6 cells may cause some cells to die, and the released DNA triggers the STING of neighboring cells. After BCP nanoparticles treatment, it has been shown that TBK1 was phosphorylated in both AML12 cells and Hepa1–6 cells. The findings demonstrated that Hepa1–6 cells significantly phosphorylated TBK1, but not AML12 cells (Figure 4D and F). Additionally, the Hepa1–6



**Figure 5.** (A) Mouse macrophages showing pro-inflammatory expression due to treatment of (a) Ser-Ag, (b) Ser-Ag<sup>INH</sup>, (c) Ser-Ag<sup>Strep</sup>, and (d) Ser-Ag<sup>PMA</sup> nanozymes. Adapted with permission from ref 148. Copyright 2022, Elsevier. (B) Real-time PCR showing anti-inflammatory activity of aspirin and FACD, *in vitro*. (a) Experiment evaluating the expression levels of TNF- $\alpha$  after a 24 h treatment with either aspirin or FACD. (b) Expression levels of IL-1 $\beta$  after a 24 h treatment with either aspirin or FACD. (c) Assessment of the expression levels of TNF- $\alpha$  after a 48 h treatment with either aspirin or FACD. (d) Evaluation of the expression levels of IL-1 $\beta$  after a 48 h treatment with either aspirin or FACD. \*:  $P < 0.05$ , \*\*:  $P < 0.01$ . (C) Aspirin and FACD anti-inflammatory effect, *in vivo*. (a) Displays a scheme outlining the drug administration and the evaluation of the anti-inflammatory effects. (b) shows the levels of PGE<sub>2</sub> in rats after treatment with either PBS, aspirin, or FACD for 5 h. (c). Histological evaluation of aspirin or FACD (each at 25 mg/kg, intraperitoneally) administered and carrageenan-induced anti-inflammatory, with the control group receiving at the same volume of sterile PBS at 5 h. P: polyester sponge implant interface. \*:  $P < 0.05$ , \*\*:  $P < 0.01$ . Adapted with permission from ref 151. Copyright 2016, American Chemical Society. Here, Ser-Ag nanozymes are serine amino acid-synthesized silver nanoparticles which show enzyme-like action. The Ser-Ag nanozymes are modified with isoniazid, streptomycin, and phosphomolybdic acid to generate Ser-Ag<sup>INH</sup>, Ser-Ag<sup>Strep</sup>, and Ser-Ag<sup>PMA</sup>, respectively. FACD is a fluorescent aspirin-based carbon dot.

cells treated with BCP nanoparticles generated higher interferons (Figure 4G).

Encapsulation of conventional drugs into liposomes for inflammatory diseases treatment, enhanced efficacy, and localization has been shown in comparison to conventional approaches.<sup>134,135</sup> Toita et al. successfully demonstrated the synergistic anti-inflammatory effect of liposome conjugated IL-10. Nanoformulation exhibited improved anti-inflammatory effect and better macrophage targeting compared to liposomes alone. Cells of the innate and adaptive immune system produce IL-10 which is employed in macrophage directed therapeutics for inflammation and related diseases.<sup>136</sup> In another study, glucocorticoids-entrapped liposomes are demonstrated for targeted delivery at inflammatory sites to improve the therapeutic ratio.<sup>137</sup> Herein, glucocorticoids act as an anti-inflammatory agent. Authors have utilized the zebrafish model and two nanoformulations, i.e., polyethylene glycol-coated and novel AmbiMACs, to confirm the biodistribution and anti-

inflammatory effect of liposomes. The outcome of the research showed that the polyethylene glycol-coated liposome has high circulation time, whereas the liposome specifically targets the macrophages. Both nanoformulations accumulate at targeted inflammatory sites, and drug encapsulation enhances anti-inflammatory effects with reduced toxic effect. However, encapsulation of the drug reduces the tissue regeneration inhibitory effect and hinders the glucocorticoid-responsive gene expression.

Dendrimers are another class of branched and multivalent nanoparticles that show an anti-inflammatory effect. Phosphorus dendrimers, i.e., polyanionic phosphorus dendrimers consisting of 12 aza-bisphosphonic groups at their surface, exhibit an anti-inflammatory response to isolated monocyte/dendritic cells and experimental arthritis model.<sup>138</sup> Other phosphorus dendrimers coated with trimannopyranosides reduce the accumulation of neutrophil in lungs of mice bearing acute lung inflammation.<sup>139</sup> It has been demonstrated

that two different phosphorus dendrimers display anti-inflammatory activity both *in vivo* and *in vitro*.<sup>140</sup> G3bis and G4bis phosphorus dendrimers occur in human inflammatory cells, effective in monocyte differentiated M0 macrophages polarized to an M1 state by lipopolysaccharide stimulation. They also inhibited the lipopolysaccharide-induced NF- $\kappa$ B activation with a decrease in nitric oxide production and CD86 and nitric oxide synthase expression. Thus, it can be suggested that anti-inflammatory activity of G3bis and G4bis phosphorus dendrimers also has effects on human macrophages. Results displayed reduced proinflammatory cytokine secretion by tissue macrophages in a mice model suffering from subchronic inflammation. Further, it is shown that the anti-inflammatory properties of polyamidoamine (PAMAM) dendrimers depend on the core and surface functionalization of dendrimers. Besides, the dendrimers are reported to inhibit cyclooxygenase-1 and cyclooxygenase-2.<sup>141</sup>

Likewise, gold nanoparticles-treated macrophages express reduction in nitric oxide synthases mRNA and nitric oxide levels triggered by lipopolysaccharide, wherein the gold nanoparticles can interfere with the nuclear factor kappa B (NF- $\kappa$ B) and STAT1 signaling pathways.<sup>142</sup> The gold nanoparticles exhibited their anti-inflammatory property *via* NF- $\kappa$ B pathways and other inflammatory mediators including cyclooxygenase-2, nitric oxide synthases, and pro-inflammatory cytokines production. NF- $\kappa$ B regulates different genes, which are involved in inflammatory responses. It is concluded that it is a novel approach toward the treatment of arthritis using gold nanoparticles.<sup>143</sup> In a similar direction, Kumawat et al. has shown the surface modification of gold nanoparticles using antibiotic, amino acid, and antioxidant molecules, wherein the engineered gold nanoparticles cotreated with lipopolysaccharide displayed reduced activity of pro-inflammatory genes including TNF- $\alpha$ , IL-6, and IL-1 $\beta$ .<sup>144</sup>

Further, gold nanoparticles tend to deposit on a variety of metal oxides including iron oxide, cobalt (II, III) oxide, and nickel oxide. The gold/metal oxides have attracted much attention because of their high catalytic performance.<sup>145</sup> Different studies, for instance, revealed gold/cerium oxide nanoparticles' antioxidant activity against Hep38 and HeLa cells in a model of cellular oxidative stress. There are reports indicating higher antioxidant activity compared to glutathione, the main cytosolic antioxidant compound.<sup>146</sup> In another study, it is presented that gold/metal oxides apart from having antioxidant activity have anti-inflammatory effects for medical utilization. A study on murine macrophages showed that the anti-inflammatory effect depends upon the metal oxides nature with particle internalization.<sup>108</sup>

Apart from gold, silver nanoparticles also encourage anti-inflammatory mechanisms by inducing the NF- $\kappa$ B response in both inflammatory and anti-inflammatory effects.<sup>147</sup> Recently, silver nanoparticles cotreated with lipopolysaccharide have been shown to downregulate the expression of IL-6, TNF- $\alpha$ , and IL- $\beta$  cytokines (Figure 5A).<sup>148</sup> It has also been well reported that silver nanoparticles can regulate the expression of pro-inflammatory genes including cyclooxygenase-2 by reducing the expression of vascular endothelial growth factor (VEGF) and hypoxia-inducible factor (HIF1 $\alpha$ ).<sup>149</sup>

Likewise, carbon nanomaterials possess an anti-inflammatory nature due to their capabilities of reducing the pro-inflammatory cytokines production. C<sub>60</sub> fullerenes have been reported to suppress mast cell-driven inflammatory response by inhibiting the cellular ROS. Fullerene derivatives can also

inhibit IL-33-induced IL-6 mRNA expression, which contributes to chronic autoimmune disease pathogenesis. Graphene oxide inhibits the release of pro-inflammatory cytokines like IL-1 $\beta$  and IL-6 expression in murine-immortalized bone marrow-derived macrophages.<sup>150</sup> In one of the studies, fluorescent aspirin-based carbon dots (FACD) have been synthesized to show the anti-inflammatory effect both *in vitro* and *in vivo*.<sup>151</sup> Results presented that the same amount, especially (100  $\mu$ g/mL) of fluorescent aspirin-based carbon dots, had higher effects than pristine aspirin (Figure 5B). Further, after 24 h of lipopolysaccharide exposure, both aspirin and fluorescent aspirin-carbon dots can inhibit the expression of TNF- $\alpha$  and IL-1 $\beta$  (Figure 5B(a and b)). Whereas Figure 5B(c and d) shows that after 48 h of post lipopolysaccharide treatment, aspirin inhibited TNF- $\alpha$  expression with no effect on expression of IL-1 $\beta$ , while fluorescent aspirin-based carbon dots displayed the inhibitory effect on both TNF- $\alpha$  and IL-1 $\beta$  expression. Further, the *in vivo* effect of fluorescent aspirin-based carbon dots by inducing inflammation in mice *via* implanting a polyester sponge with 1% carrageenan (inflammation inducer) soaked subcutaneously for 30 min after fluorescent aspirin-based carbon dots administration was studied (Figure 5C(a)). Figure 5C(b) clearly displays that carrageenan exposure increased expression of prostaglandin E<sub>2</sub> in serum, which can be significantly decreased by aspirin and fluorescent aspirin-based carbon dots treatment. Further, hematoxylin and eosin staining shown in Figure 5C(c) discloses that control groups treated with carrageenan exhibit clear inflammatory cell layers, with various neutrophils infiltration under the epidermis. However, fluorescent aspirin-based carbon dots-treated rats show much smaller inflammatory cell layers with only scattered neutrophils infiltration beside the epidermis. All of these data clearly suggest that fluorescent aspirin-based carbon dots possess effective anti-inflammatory function *in vivo*.

From the above discussion, it can be concluded that synthesized nanomaterials find utility in biology and medicine due to their anti-inflammatory properties. In this direction, Johnson et al. proposed a study by selecting surfactin-loaded k-carrageenan oligosaccharides-linked cellulose nanofibers (CO-CNF) against periodontitis. Three different surfactin-loaded nanoparticles have been developed by increasing the concentration of surfactin. Surfactin is a biosurfactant exhibiting anti-inflammatory, antibacterial, antiviral, anticancer, antifungal, and thrombolytic activities.<sup>152</sup> Thus, the properties of surfactin can be used against periodontitis, a disease depicted by alveolar bone loss and gingival inflammation, which is associated with a high level of pro-inflammatory cytokines.<sup>153</sup> The study was performed by three different concentrations of surfactin, wherein 200SNPs (200 mg surfactin-loaded CO-CNF nanoparticles) reduced the bacterial viability by inducing the oxidative stress in periodontal pathogens *Fusobacterium nucleatum* and *Pseudomonas aeruginosa*. Additionally, 200SNPs can also reduce the ROS and cytokine production under inflammatory conditions which is useful in the treatment of periodontitis.<sup>154</sup>

Similarly, chitosan-alginate nanoparticles, because of the antimicrobial and anti-inflammatory activity, find suitable applications in targeted therapy for cutaneous bacterium, *Propionibacterium acnes*. The chitosan-alginate nanoparticles disrupted the bacterial cell wall by inflammatory cytokine IL-12 production in human monocytes and IL-6 in human keratinocytes. The chitosan-alginate nanoparticles also reduce

the risk of resistant species.<sup>155</sup> The engineered polymeric nanoparticles of chitosan display antimicrobial activity and anti-inflammatory activity, which is prepared using chitosan nanoparticles and antimicrobial peptide. They show fast mortality and have the ability to bind to lipopolysaccharides and downregulate NF- $\kappa$ B and mitogen-activated signaling pathways of protein kinase.<sup>156</sup>


Additionally, nanomaterial platforms functionalized with targeting ligands can serve as powerful tools for the management of inflammatory disease, and several other biological applications are indicated in Table 2. The functionalization of nanomaterials with the specific molecule helps in the enhanced activity of nanomaterials including delivery to the targeted site, lower doses of required antibiotic, control toxicity, and better penetration; for example, RBC membrane-coated nanomaterials show extended blood circulation and have improved cancer targeting activity.<sup>157–159</sup> The nanocarrier functionalization helps in the improvement of target specific immune cell receptors, improvement of adjuvant, and antigen delivery toward the discriminatory immune response.

The engineered cell membrane-coated nanomaterials can efficiently be utilized in targeting and treating localized lung inflammation *via* systemic administration.<sup>160</sup> In this context, Park et al. proposed the targeted delivery of dexamethasone (DEX) to inflamed lungs using nanoparticles covered with a genetically engineered cell membrane.<sup>160</sup> In the inflamed endothelial cell, the expression of pro-inflammatory cytokines of specific surface markers including VCAM-1 or ICAM-1 has been upregulated. The anti-inflammatory drug dexamethasone loaded into poly(lactic-*co*-glycolic acid) caused an increased level of pro-inflammatory cytokine IL-6 and TNF. The study concludes the significant therapeutic efficacy *in vivo* with the targeting specificities.<sup>160–163</sup> Pro-inflammatory cytokines showed increased expression in the presence of nanoparticles containing hydrocarbon groups-dominated surface chemistry adding to the formation of protein corona, whereas amine-rich coatings led to increased expression of anti-inflammatory markers.<sup>164</sup> In another study, budesonide-based site-specific delivery to inflamed tissue by a mannosylated nanostructured lipid carrier (MN-NLCs) system was proposed, to avoid drug elimination.<sup>165</sup> Thus, a stronger interaction with targeted tissues is necessary to achieve the full potential of the antibiotic and enhancement of therapeutic outcomes.<sup>166</sup>

The mechanism of nanomaterial-mediated cytotoxicity has been well documented and related to diverse physiological changes like membrane damage and cytoskeleton modification. Molecular pathways of cytotoxicity include mitochondria damage, disturbance of lysosome functioning, oxidative damage of DNA, over-expression of pro-inflammatory cytokines, etc.<sup>167,168</sup> However, mechanistic studies pertaining to the molecular mechanism of nanomaterial-induced immunosuppression are still in a nascent stage. Nanoparticle-mediated immunosuppression can be due to a direct interaction of the nanomaterial with the immune system or used to deliver immunosuppressive drugs. For example, studies have demonstrated poly(lactic-*co*-glycolic acid), chitosan, polylactic acid nanomaterials, and dendrosomes to effectively suppress type-I and type-II allergies and treat animal models of autoimmune uveoretinitis with betamethasone-loaded polylactic acid.<sup>169,170</sup> They have also been used to deliver poorly bioavailable immunosuppressive drugs like cyclosporine and tacrolimus *via* polymeric nanoparticles, liposomes, and lipid

**Table 2. Different Types of Nanomaterials, Their Surface Modification to Impart Functional Properties, Mechanism, and Applications in Biology and Immunology**

Nanomaterials	Molecules for surface modification	Action mechanism	Applications	ref
Gold nanocages	Poly( <i>N</i> -isopropylacrylamide) (pNIPAAm)	Conformation changes in response to temperature variations	Controlled release of anticancer drug in near-infrared region	174
Gold nanoparticles	Snake venom protein toxin NN-32 with PEG ligand	Preventing nonspecific binding of peptides and enzymes	Increase cytotoxicity and apoptosis against human breast cancer cell lines	175
Superparamagnetic iron oxide nanoparticles	Dendritic guanidine	Enhances cellular transportation	Magnetic resonance imaging	176
Silver nanoparticles	Titanium substrate	Fabrication of antibacterial biocomposites	Antimicrobial and biomedical applications	177
Gold nanoparticles	N-Heterocyclic (NHC) carbene	Selective and active catalytic reduction of CO <sub>2</sub> to CO in water	Catalytic applications	178
Multivalent gold and silver nanomaterials	Herceptin antibody	Targeting particles for imaging and photothermal therapy	Possesses six-fold higher affinity for cancer cell imaging in comparison to noncancer cells	179
Gold nanoparticles	Polyoxometalates and lysine	Polyoxometalates and lysine provide functional surfaces and selectively direct nanoparticles to bacterial and mammalian cells	Potent antimicrobial and cytotoxic materials against A549 human lung carcinoma cells	180
Mesoporous silica nanoparticles	Gold particles	Biocompatible capping agent and add weight to each individual mesoporous silica nanoparticles to increase the density	DNA and drugs delivery into cells and tissues	181
Polymeric nanomaterials	1,25-Dihydroxyvitamin D3 (aVD <sub>3</sub> )	Anti-inflammatory and immunomodulatory effects due to dendritic cells modulation	Induce antigen-specific immune tolerance, important in the treatment of autoimmune diseases	182



**Figure 6.** Interferon- $\gamma$  and TNF- $\alpha$  inhibition by iron oxide nanoparticles treatment. (A) Representative light micrographs showing footpad sections that were IFN- $\gamma$ -stained. The original magnification was  $\times 200$ . The box in the image highlights subcutaneous regions where IFN- $\gamma$  signals were observed in the ovalbumin-sensitized group that did not receive treatment. (B, C) Characteristic light micrographs of footpad sections were IFN- $\gamma$  and TNF- $\alpha$ -stained, respectively. The original magnification was  $\times 400$ , and the arrows in the images indicate positive cells. (D, E) Iron oxide nanoparticles have a differential effect on splenocyte for antigen-specific IFN- $\gamma$  and IL-4 production. Splenocytes isolated from each test group of mice were cultivated in ovalbumin ( $50 \mu\text{g}/\text{mL}$ ) for 72 h, and collected supernatants were measured (D) IFN- $\gamma$  and (E) IL-4 by enzyme-linked immunosorbent assay. Adapted with permission from ref 70. Copyright Creative Commons Attribution, NonCommercial (unported, v3.0) License.


nanomaterials.<sup>63,65,171–173</sup> The next section highlights the

mechanism of nanomaterial-mediated direct immunosuppres-

sion and probable suppression cascades.

#### 4. ACTION MECHANISM OF IMMUNOSUPPRESSIVE NANOMATERIALS

Cytokines like transforming growth factor- $\beta$  (TGF- $\beta$ ) and IL-10 and immune cells like T regulatory cells and myeloid-derived suppressor cells contribute toward suppressing the immune system. Initial reports of nanoparticle-mediated



**Figure 7.** *In vivo* response of gold nanoparticles (AuNPs) downregulating the IL-1 $\beta$ -induced responses. (A) Mechanisms of gold nanoparticles' down-regulation of IL-1 $\beta$  cellular responses. (B) IL-1 $\beta$  (2500 ng/kg) injected C57/BL6 mice. Gold nanoparticles (100 nmol Au/kg) were simultaneous injected into some of the animals. Adapted with permission from ref 192. Copyright 2012, John Wiley and Sons. (C) The Western blot assay was used to assess the protein expression of inflammatory cytokines in RAW 264.7 macrophages. The nanoparticles tested were Cur-Au, Cur-Au<sup>INH</sup>, Cur-Au<sup>Tyr</sup>, and Cur-Au<sup>Qrc</sup>, represented by a, b, c, and d, respectively. Adapted with permission from ref 144. Copyright 2022, American Chemical Society. Here, Cur-Au nanoparticles are curcumin-reduced gold nanoparticles, which are further surface modified with isoniazid, tyrosine, and quercetin to generate Cur-Au<sup>INH</sup>, Cur-Au<sup>Tyr</sup>, and Cur-Au<sup>Qrc</sup> nanoparticles, respectively.

immunosuppression was detected in carbon nanoparticles such as CNTs and fullerenes. It has been proved that C57BL/6 mice intranasally exposed to CNTs suppressed systemic T cell activation in a direct cyclooxygenase- and cyclooxygenase2-dependent manner. Cyclooxygenase2 has been implicated in activating pSTAT3 which can be an underlying mechanism of regulatory T cell production and trafficking and the generation of an immunosuppressive setting. CNTs-mediated immunosuppression could be reversed with the aid of cyclooxygenase2 inhibitor "ibuprofen" or in the case of cyclooxygenase2 knockout mice. This mechanism of immunosuppression involved TGF- $\beta$  and IL-10 leading to prostaglandin release following phagocytosis of CNTs by alveolar macrophages, leading to T cell dysfunction and immune suppression. The immune suppressive property of fullerene C<sub>60</sub> has been established in a delayed type of hypersensitivity model induced by methyl bovine serum albumin. Nano C<sub>60</sub> treatment significantly alleviated pro-inflammatory cytokines IL-6 and IL-17 and enhanced regulatory T cell population within splenocytes indicating the suppression of pathogenic Th17 phenotype and induction of T regulatory cells, which contribute toward controlling a pathogenic environment.<sup>183</sup> Mast cell and peripheral blood basophil activation by IgE and Fc $\epsilon$ R1 interaction is a primary mediator of systemic anaphylaxis or antigen driven type-I hypersensitivity. C<sub>60</sub> fullerene exposure to skin, lung mast cells, and basophils inhibited antigen-sensitized IgE production. Mechanistic studies also revealed the C<sub>60</sub>-mediated inhibition of ROS production in the mast cells and basophil. A direct contribution of Syk, a tyrosine kinase in its role in Fc $\epsilon$ R1

signaling cascade and hypersensitivity, is previously known.<sup>184</sup> Proteomics data revealed that initial fullerene treatment inhibited tyrosine kinase Syk more than 50-fold on antigen stimulation, thereby contributing to immunosuppression.<sup>185</sup>

ROS production can lead to DNA and protein damage, even altering the phospholipid bilayer membrane, compromising cellular activity and repair mechanisms. Quenching of ROS is desirable to limit inflammation and decrease damage. Metal oxide nanoparticles have also been explored as potential immunosuppressants and as ROS quenchers. Cerium oxide nanoparticles exhibit different oxidation states for cerium of +3 and +4, which has been attributed as a crucial factor to reduce ROS and nitric oxide levels in lipopolysaccharide-treated macrophages. Furthermore, cerium oxide nanoparticles could also upregulate superoxide dismutase-2 and inhibit inducible nitric oxide at both mRNA and protein levels as well.<sup>186,187</sup> However, the antioxidant property of cerium oxide nanoparticles also depends on their size and oxidation state. Cerium in +3 oxidation states and smaller-sized (~3 nm) cerium oxide nanoparticles were able to suppress ROS production in fibroblast cells as compared to 8 nm particles.<sup>188</sup>

Furthermore, iron oxide nanoparticles have been observed to suppress the humoral response of a T cell-dependent antigen, i.e., ovalbumin. Iron oxide nanoparticles can block T helper cell activation and thereby limit production of cytokines like IFN- $\gamma$ , IL-6, and TNF- $\alpha$ , which are mainly involved in inflammation. In a supporting report, iron oxide nanoparticles suppressed ovalbumin-induced delayed type hypersensitivity in a mouse footpad by suppressing Th1 cytokines like IFN- $\gamma$  and TNF- $\alpha$ .<sup>70</sup> Immunohistochemical staining showed that iron

oxide nanoparticle therapy significantly reduced the signals of IFN- $\alpha$ , IL-6, and TNF- $\alpha$ , which were frequently found to be perivascular in the dermis layer. Additionally, mice exposed to 0.6 and 10 mg iron/kg of iron oxide nanoparticles had considerably less CD3<sup>+</sup> and F4/80<sup>+</sup> cells than the vehicle-treated control group (Figure 6A–C). Results displayed that 50 g/mL of ovalbumin treatment can restimulate the splenocytes from nonsensitized and ovalbumin-sensitized mice in culture for 72 h to promote the generation of antigen-specific cytokines to study the iron oxide nanoparticles effect on the functioning of T cells in delayed-type hypersensitivity (DTH) reactions. Effective induction of antigen-specific T cell reactivity can be seen in Figure 6D and E, showing ovalbumin-sensitized groups possess significant induction of IFN- $\alpha$  and IL-4 by ovalbumin stimulation compared to nonsensitized groups. Iron oxide nanoparticles suppress IFN- $\alpha$  production, which is consistent with decreased footpad edema (Figure 6D). On the other hand, as shown in Figure 6E, its exposure also increases the production of IL-4.

Mechanistically, using a primary murine microglial cell model stimulated with lipopolysaccharide, it has been proven that iron oxide nanoparticles accumulate in lysosome of microglia enhancing lysosomal permeability and decreasing the activity of cathepsin B, which is a secretory enzyme responsible for the activation of IL-1 $\beta$  converting (ICE) protease that converts immature pro IL-1 $\beta$  to active IL-1 $\beta$  and stimulate the inflammatory cascade.<sup>189</sup> Iron oxide nanoparticles thereby inhibit IL-1 $\beta$  and negate pro-inflammatory cytokine release. A corollary article demonstrated the inhibition of lipopolysaccharide and tetanus toxoid pro-inflammatory cytokines IL-6, IL-1 $\beta$ , TNF- $\alpha$ , IL-12p70, and IFN- $\gamma$  secretion as well as CD4 T cell activation by human monocyte-derived dendritic cells with PVA-coated iron oxide particles.<sup>190</sup>

Gold nanoparticles have been proven to be an excellent inclusion in the arsenal to combat inflammatory responses like rheumatoid arthritis, inflammatory bowel disease, and bacterial infection.<sup>191</sup> An initial *in vitro* mechanistic study revealed that gold nanoparticles inhibit lipopolysaccharide-induced nitric oxide production and nitric oxide synthase expression in lipopolysaccharide-induced RAW 264.7 macrophages. It may be attributed to the inhibition of Akt-NF- $\kappa$ B pathway and hence secretion of pro-inflammatory cytokines like TNF- $\alpha$ , and IL-6. Furthermore, phosphorylation of STAT1 was also inhibited via downregulation of type-I interferons expression.<sup>142</sup> In yet another corollary report, it is demonstrated that IL-1 $\beta$  regulates inflammatory signaling (phosphoinositide 3-kinases, hypoxia-inducible factor-1 $\alpha$ , TNF- $\alpha$ ) inhibition by citrate-stabilized gold nanoparticles both *in vitro* and *in vivo* (Figure 7). Smaller gold nanoparticles are more effective in downregulating pro-inflammatory cytokine expression.<sup>192</sup>


Figure 7A displays the mechanism underlying regulatory effects of gold nanoparticles over IL-1 $\beta$ -induced inflammatory response *in vivo*. Further, the result has been validated by treating 4 week old male mice with IL-1 $\beta$ , gold nanoparticles, and in combination. The Western blot image in Figure 7B shows that IL-1 $\beta$  treatment induces inflammatory response in mice by increasing phosphoinositide 3-kinases activity and hypoxia-inducible factor-1 $\alpha$  accumulation in a cellular fraction as well as enhanced TNF- $\alpha$  concentration in blood. Whereas treatment of both IL-1 $\beta$  and gold nanoparticles leads to reduction in all three inflammatory markers in comparison to the IL-1 $\beta$ -treated positive control. Macrophages cotreated with gold nanoparticles and lipopolysaccharide have also been

shown to reduce the activity of pro-inflammatory genes and protein (IL-1 $\beta$ , TNF- $\alpha$ , and IL-6) to normal levels as presented in Figure 7C.<sup>144</sup> Additionally, it has been correlated that the anti-inflammatory property of gold nanoparticles inhibits CpG oligodeoxynucleotides (CpG-ODN)-mediated toll-like receptor-9 signaling and henceforth c-Jun N-terminal kinase (JNK) and the NF- $\kappa$ B inflammatory pathway in RAW 264.7 murine macrophages. Gold nanoparticles could efficiently bind to high mobility box-1 (HMGB-1) protein and inhibit toll-like receptor-9 translocation to the phagosome in response to CpG-ODN.

Furthermore, smaller-sized gold nanoparticles can accumulate in lysosomes, and they are more potent in enhancing cathepsin-K, cathepsin-L, cathepsin-S, and cathepsin-B expression and blocking toll-like receptor-9 translocation. Other metal oxide nanoparticles, like titanium oxide nanoparticles < 100 nm, have been demonstrated to be immunomodulatory and decrease lipopolysaccharide-stimulated T lymphocyte proliferation in splenocytes, but the exact route of action has not been studied in detail.<sup>193</sup>

Apart from metal- and metal oxide-derived nanoparticles, polymer nanomaterials and macromolecules have also been explored as immunosuppressants. The polymer nanomaterials have been explored for their potential to deliver immunosuppressive drugs, and to some extent, direct immune suppression has also been addressed. Initial instances of polystyrene nanoparticles < 50 nm alleviated lung inflammation, epithelial mucus production, and serum IgE and Th2 response against allergen ovalbumin exposure and depicted inhibition of lung dendritic cell expansion leading to generation of tolerogenic microenvironment against allergen challenge.<sup>194</sup> Getts et al. demonstrated decoration of polystyrene nanoparticles with encephalitogenic antigen to prevent the onset and that it modifies the disease progression in a mouse model of multiple sclerosis by inducing T cell tolerance and generation of regulatory T cells of experimental autoimmune encephalomyelitis (EAE).<sup>195</sup>

However, surface decoration of polystyrene nanoparticles can act as a double-edged sword and may result in an inflammatory response. Sulfonate- and phosphonate-functionalized polystyrene nanoparticles are reported to significantly enhance CD4<sup>+</sup> T cell proliferation and a pronounced shift to Th1 phenotype with IFN- $\gamma$  production.<sup>196</sup> The polymer macromolecule “dendrimer” has been described to exhibit tremendous anti-inflammatory potential. Initial reports of dendrimers possessing hydroxy terminal polyamidoamine inhibit endotoxin-mediated inflammation in microglia. The dendrimers efficiently suppress lipopolysaccharide-mediated MAPK phosphorylation and inhibit secretion of pro-inflammatory mediators like nitric oxide, IL-6, etc.<sup>197</sup> Moreover, dendrimers with highly branched chains have allowed for multivalent interactions with multiple cellular and molecular targets in autoimmune diseases such as rheumatoid arthritis. An azabisphosphonate (ABP)-capped dendrimer has been synthesized, which selectively targets human monocytes and directs them toward an anti-inflammatory phenotype and inhibits IL-2-dependent proliferation of CD4<sup>+</sup> T lymphocytes. In mouse models relevant to human rheumatoid arthritis, IL-1 $\alpha$ <sup>-/-</sup> and K/BxN serum transfer model, ABP-dendrimer suppressed serum IL-1 $\beta$ , TNF- $\alpha$ , IL-6, and IL-17, while increasing the IL-10 level which demonstrated a skewing of inflammatory response toward an anti-inflammatory phenotype. Mechanistically, the azabisphosphonate-dendrimer in-




**Figure 8.** (A) (a) Confocal microscopy showing particles internalization by dendritic cells and (b) time dependent uptake of 1 μM poly(lactic-co-glycolic acid) microparticles. (B) Poly(lactic-co-glycolic acid) microparticles coculture with dendritic cells leads to reduced phosphorylation of two key intermediates, (a) TAK1 and (b) IKKβ, in the nuclear factor kappa B (NF-κB), canonical activation pathway. (C) Coculture with poly(lactic-co-glycolic acid) microparticles drives downregulation of the inflammatory transcription factor NF-κB in lipopolysaccharide (LPS)-stimulated dendritic cells. Adapted with permission from ref 199. Copyright 2018, American Chemical Society.

hibited monocyte and bone marrow monocyte precursor differentiation into osteoclasts, which is a major component of bone erosion. Moreover, it also suppresses rheumatoid arthritis by decreasing c-FMS and RANK expression in monocytes which directs monocyte differentiation into the osteoclast.<sup>138</sup> Shaunak et al. have demonstrated a glucosamine 6-sulfate dendrimer inhibition of lipopolysaccharide-toll-like receptor-4-mediated production of pro-inflammatory cytokines and chemokines (MIP-1α, CXCL8, MIP-1β) from immature human dendritic cells and macrophages.<sup>198</sup>

PLGA is an attractive drug delivery vehicle due to its biocompatibility. The inert potential of poly(lactic-co-glycolic acid) as an active immune suppressant has been demonstrated against lipopolysaccharide-exposed bone marrow-derived dendritic cells. Confocal fluorescent microscopy images with all planes shown in Figure 8A(a) illustrate the internalization of particles in dendritic cells. Further, flow cytometry data

indicate no significant difference in internalization of poly(lactic-co-glycolic acid)-50, poly(lactic-co-glycolic acid)-75, and poly(lactic-co-glycolic acid)-100 at different time points of phagocytosis (Figure 8A(b)). Poly(lactic-co-glycolic acid) exposure resulted in intracellular accumulation of sodium-L-lactate which inhibited phosphorylation of transforming growth factor-β-activated kinase 1 (TAK1) and inhibitor of nuclear factor kappa-B kinase subunit beta (IKKβ) and downregulated expression of inflammatory transcription factor NF-κB.<sup>199</sup> Figure 8B(a) displays that low molecular poly(lactic-co-glycolic acid) particles reduced the phosphorylation of TAK1 at different time points, which is comparable to well-known TAK1 inhibitor, i.e., 7-oxozeaenol. Phosphorylation of IKKβ has also been investigated in dendritic cells, following exposure with poly(lactic-co-glycolic acid) particles. Results in Figure 8B(b) show that the phosphorylation level of IKKβ seems not as stark as of TAK1, particularly at the 24 and 72 h



**Figure 9.** (A) Injection of silica (silicon dioxide) nanoparticles shows a correlation with change in the liver index. (B) Inflammatory cell aggregation in hepatic portal space indicates their infiltration. (C) Demonstration of the infiltration of inflammatory cells, primarily lymphocytes, in the hepatic strands of the lobules. Adapted with permission from ref 211. (D) The average concentration of copper present in the blood and organs of mice following a 6-week exposure to copper oxide (CuO) nanoparticles. (E) Concentrations of various cytokines in the supernatants of spleen cell cultures from mice were treated with CuO nanoparticles via inhalation for a duration of 6 weeks. (F) Spleen lymphocyte proliferative activity after 6-week inhalation of CuO nanoparticles in mice. Adapted with permission from ref 212. Copyright 2022, Creative Commons Public Domain Mark 1.0.

time points. Further, the downregulation of pro-inflammatory surface markers and the decreased production of pro-inflammatory IL-12 following ingestion of poly(lactic-co-glycolic acid) particles by dendritic cells were investigated. The outcome exposed the decrease in NF-κB expression following coculture of poly(lactic-co-glycolic acid) particles with sodium-L-lactate even with subsequent lipopolysaccharide stimulation (Figure 8C). In a pathbreaking finding, negatively charged poly(lactic-co-glycolic acid) particles reduced inflammation in mouse models imparted by sulfate-induced colitis, lethal flavivirus encephalitis, and thioglycolate-induced peritonitis and promoted tissue repair and reduced monocyte infiltration at inflammatory foci. Mechanistically, these particles were opsonized by inflammatory monocytes *via* macrophage receptors with a collagenous structure (MARCO). In contrast, positively charged and neutral particles failed to alleviate the disease burden and inflammatory responses.<sup>200</sup>

Even though nanomaterials possess inherent immune suppressive properties, further exploration deducing the mechanism is necessary to avoid adverse effects like myelosuppression. Moreover, a single marker like TGF-β cannot solely be used to identify immunosuppressive properties, as a combination of TGF-β along with IL-6 and IL-1 also induces an inflammatory Th17 phenotype. Nanomaterial-mediated immunosuppression should be characterized in detail with the inclusion of TGF-β and IL-10 secreting macrophages, dendritic cells, and regulatory T cells.

## 5. COMPLICATIONS ASSOCIATED WITH NANOMATERIALS-MEDIATED IMMUNE SUPPRESSION

As discussed in the above sections, nanomaterials can be utilized in modulation of immune responses by either

stimulation or inhibition activities due to their unique physicochemical and surface properties. The size, shape, composition, surface/volume ratio, crystal planes, stability, hydrophobicity, hydrophilicity, surface charge, surface corona, and surface functionalization of nanomaterials are the essential properties that contribute to their immune responses. However, despite the several potential advantages of employing nanomaterials in immunology, issues concerning the materials' biosafety persist to a greater extent. Like, under certain circumstances, modulating the effect of nanomaterials goes uncontrolled and leads to several adverse effects and immunotoxicity. Accounts showed that during immune stimulation, the interaction of nanomaterials with cell-surface receptors (e.g., in leukocytes) and other innate immune cells components leads to the generation of a cytokine storm, interferon response, and/or lymphocyte activation resulting in immunotoxicity.<sup>79</sup> Various reports have illustrated that the interaction of nanomaterials may result in immunotoxicity and produce a variety of immunological reactions that severely affect the immune system.<sup>21,201</sup> Thus, critical questions need to be addressed regarding how distinct innate immune systems interact with synthetic nanomaterials, as imbalance of the immune system exerts a damaging effect on the body. Immunotoxicity causes immunosuppression or immunostimulation which may lead to tumor growth, autoimmune diseases, or vulnerability to infectious diseases. Immunosuppression may quell the normal immune response essential for maturation and proliferation of immune cells, whereas undesired immune stimulation may result in hyper-reactions called allergic reactions.<sup>202</sup>

Nanomaterials-mediated immune stimulation and immunotoxicity also depend on the activation of phagocytic cells, which leads to their engulfment. It has been reported that upon

exposure to a normal dose, nanomaterials can be engulfed into phagocytes, whereas toxic concentration induces ROS generation from phagocytic cells leading to tumorigenesis and cell death.<sup>203</sup> In addition, the generation of ROS by activated macrophages can be interpreted as an attempt by the immune system to destroy the nanomaterial's surfaces. Increased ROS generation acts as a secondary messenger to enhance the inflammatory immune response. It also induces the production of several proinflammatory cytokines like IL-6, IL-12, and TNF- $\alpha$  as well as play an important role in regulation of T-lymphocytes<sup>204</sup> and fibrosis.<sup>205,206</sup>

The cytotoxic behavior of nanomaterials mainly depends on their several physicochemical properties including morphology, shape, size, surface chemistry, surface area, composition, and action mechanism.<sup>17,124,144,148,207–209</sup> Results revealed that exposure of nanomaterials induces ROS generation in a pro-inflammatory state, which further leads to membrane, protein, and lipid damage. Immune system continuous activation causes the development of several allergic and autoimmune diseases. Reports recommend that mesoporous silica nanoparticles alter the gene expression analysis of RAW 264.7 at a nontoxic dose, whereas nonporous silica demonstrates the minimum effect to gene transcription.<sup>210</sup> Other studies have also showed that silica nanoparticles with a 10 nm size induce hyperplasia in liver Kupffer cells and inflammation of inflammatory cells *in vivo* as represented in Figure 9A–C.<sup>211</sup>

In addition to silica nanoparticles, continuous exposure of copper oxide nanoparticles to humans also induces an immuno-toxic response. Their toxicity in mice after 6-week continuous exposure at a concentration of 32.5  $\mu\text{g}/\text{m}^3$  has been investigated.<sup>212</sup> After continuous inhalation, copper oxide nanoparticle concentration was significantly increased in mice lungs and liver (Figure 9D) and enhanced the proliferative response of T-lymphocytes. The exposure also increased the production of IL-12p70, IFN- $\gamma$  Th1-cytokine, and Th2-cytokines IL-4 and IL-5, whereas TNF- $\alpha$  and IL-6 levels remained unchanged (Figure 9E). Phagocytic activity of granulocytes has also been suppressed, while no significant change in the phagocytosis of monocytes was observed. Comparing mice exposed to copper oxide nanoparticles to controls, the basal proliferative activity of isolated splenocytes was considerably higher in the exposed mice as shown in Figure 9F. Thus, results collectively indicate that innate immunity of mice was significantly affected by the subchronic inhalation of copper oxide nanoparticles which modulate the immune response.

Zinc oxide nanoparticles also proved toxic to primary and immortalized immune cells. Their intranasal exposure leads to immunotoxicity in *in vivo* mice as evidenced by splenocyte death due to Zn<sup>2+</sup> release from zinc oxide nanoparticles and their internalization into immune cells. Increased intracellular ROS generation might be attributed as another factor toward zinc oxide nanoparticles-mediated toxicity effect.<sup>213</sup> Apart from humans and mice, zinc oxide nanoparticles also exhibit immuno-toxic effects in aquatic life due to their extensive use in cosmetics and other industries. Zinc oxide nanoparticles are described to induce immunotoxicity in crucian carp (*Carassius carassius*) as several inflammatory cells were filled in the liver's central vein accelerated by zinc oxide nanoparticles. Results also revealed the elevation of neutrophil extracellular traps (NETs) levels composed of myeloperoxidase, citrullinated histone 3, and neutrophil elastase.<sup>214</sup>


Furthermore, other metal oxides like titanium dioxide nanoparticles were also proven to be toxic to humans and mice. After exposure for 9 consecutive months, titanium dioxide nanoparticles were shown to be accumulated in the thymus and led to reduction of lymphocyte subsets including CD3<sup>+</sup>, CD4<sup>+</sup>, CD8<sup>+</sup> T, B cell, and natural killer (NK) cells.<sup>215</sup> Additionally, titanium dioxide nanoparticles enhanced expression of NF- $\kappa$ B, I $\kappa$ B kinase 1/2, IL-1 $\beta$ , IL-4, and neutrophil gelatinase-associated lipocalin, whereas suppressed the expression of I $\kappa$ B and trefoil factor 1. Thus, it can be concluded that titanium dioxide nanoparticles exert significant toxicity to T cells, lymphoid organs, and immune cell homeostasis.

Other than metal oxide nanoparticles, carbon-based nanomaterials are proven to exert immuno-toxic effects in various life forms.<sup>216,217</sup> A study showed that 13 weeks of exposure of C<sub>60</sub> fullerenes to mice via nose inhalation leads to increases in rat's monocyte chemoattractant protein (MCP)-1 (rats) and mice macrophage inflammatory protein (MIP)-1 $\alpha$  in bronchoalveolar lavage (BAL) fluid. All C<sub>60</sub> fullerene-exposed rats indicated phenotype shifts in cells recovered from the bronchoalveolar lavage regardless of the exposure level. Other studies have also showed the immuno-toxic effect of C<sub>60</sub> fullerenes as they can provoke inflammation of monocytes-macrophage cells.<sup>216</sup> Fullerenes also induce an excessive expression of specific cytokines and chemokines, including IL-8 and monocyte chemoattractant protein-1.

## 6. FUTURE STRATEGY TO FINE-TUNE SURFACE PROPERTIES OF NANOMATERIALS TO ELICIT THE DESIRED IMMUNE RESPONSES

From the above analysis, it is apparent that nanotechnology applications in immunology depend on the appropriate fabrication of nanomaterials with molecules exhibiting natural polymer-like properties and the ability to evade the immune system. For the immunology aspects, nanomaterials should be developed in a manner that escapes from the immune system. Nonetheless, the interactions of nanomaterials with the immune system can be governed by controlling their shape, surface charge, size, steric effect, and hydrophobicity/hydrophilicity behavior. There are several ways to mitigate the immune response of nanomaterials including biocompatible materials, immuno-manipulative payload, and coating of nanomaterials with biomimetic or synthetic entities including several receptors, macromolecules, or membranes from endogenous cells or sterically inhibited polymers.<sup>218</sup> These modifications can produce synthetic engineered, "stealth" nanoparticles which go undetectable by most immune cells, allowing them to release their payload at targeted site. Further, surface modification of the nanomaterials using a specific ligand or polypeptide can alter their functionality from passive to active targeting. The "invisibility" of nanomaterials to the immune system can be achieved by several methods, and each of the procedures has advantages and disadvantages.

In this regard, polyethylene glycol and other hydrophilic polymers are proved to be ideal candidates as a coating over a nanoparticle's surface with water molecules, which facilitates their escape from macrophages and opsonization.<sup>219,220</sup> Polyethylene glycol surface functionalization can also significantly increase the half-life of nanoparticles in bloodstream. All of these studies enable the discovery of new natural compounds mimicking molecules to escape the immune system. Nanomaterials can also be successfully used to reduce the toxicity of therapeutic vaccines. To create effective vaccines



**Figure 10.** Schematic representation of current limitations and future aspects of employing nanomaterials in immunomodulation.

and vaccine delivery systems, medical researchers attempted to alter nanomaterials in various ways. For instance, the use of recombinant TNF- $\alpha$  vaccines has been prohibited due to their severe side effects. However, conjugation of the vaccine to polyethylene glycol-coated gold nanoparticles has demonstrated an enhanced maximum tolerated dose.<sup>220</sup>

In the human body, each immune cell behaves differently in response to nanomaterial exposure. For instance, zinc oxide nanoparticles induce high toxicity effect to monocytes, whereas no toxic response has been observed in the case of lymphocytes.<sup>221</sup> Although it would be impractical to detect every interaction that might take place due to the large variety of immune cell types and nanomaterials, focused research into the more promising subcategories of nanomaterials might be appropriate to expand this technology. Therefore, apart from the modifications, several research developments have been required to fulfill nanomaterials' early promise in applications for drug delivery.

Combining a few immuno-manipulative strategies together for "synergistic effect" can be evolved as a new area of development by exploring the different materials and surface modification strategy. As discussed earlier, all of the immune cells react differently in response to different analytes. To overcome this factor, several nanomaterial designs can be combined to produce an appropriate immunological response. Although several aspects have been investigated regarding the immunomodulatory effect of surface modified nanomaterials, further research is required to explore the immunogenic potential of these complexes and modifications. A lot of research is still required in this area, while the current approaches provide a very fascinating picture of theranostics for the future of science and health.

However, the ideal balance of nanostructure attributes is highly challenging due to the vast array of potential nanostructure bases, chemical changes, payload alterations, and surface modifications/coatings. Even after identification of the ideal mixture for the treatment or diagnosis of disease, the immunological repercussions must be carefully assessed. This is especially true since there is not a single "catch-all"

nanomaterial that can be applied in all circumstances. Many times, particular characteristics are necessary that significantly change toward how well the nanomaterial functions. The future of employing nanomaterials in a range of applications, including medication delivery and theranostics, is quite promising, even though there may be much investigation to be done. Consequently, nanomaterials can be engineered and utilized to trigger a variety of immunological responses, indicating their importance in the immune system or immune cells treatment. Figure 10 illustrates nanomaterial-mediated toxicity to the immune system and various future aspects.

In the discussed milieu, natural nanomaterials have also attracted much attention due to their potential in biomedical applications. Currently, cytoplasmic ribonucleoprotein is being studied as a therapeutic for delivery of drugs and antigen.<sup>222</sup> Additionally, other biomimetic particles are being developed for their application in the biomedical industry with exosomes (natural extracellular vesicles).<sup>223</sup> Overall, the development of new, biocompatible imaging and drug delivery systems based on templates taken from viruses, pathogens, or inspired by endogenous particles, all of which employ immune recognition and/or immune evasion strategies, has been fine-tuned by evolution.

## CONCLUSION

The immunomodulatory effects of nanomaterials have attracted significant attention, but the ideal balance between different characteristics of nanomaterials is challenging. Therefore, efforts are being made to tailor the physicochemical and surface properties of different nanomaterials to unitize their full biomedical capabilities. In this review, we discuss recent trends in nanoengineering, which are at the forefront for targeted immunomodulation and do not induce immunotoxicity. The signaling pathways associated with nanomaterial-based immunotherapy have also been explored. Further, recommendations are provided for regulating different immune responses toward target specific drug delivery and to reduce possible risks to human health, if any. Nevertheless, the existing approaches are not enough to realize the full potential

of nanomaterials, and future-in-depth studies are required for nanomedicine applications of immunomodulatory-nanomaterials.

## AUTHOR INFORMATION

### Corresponding Authors

**Hemant Kumar Daima** – Department of Biochemistry, School of Life Sciences, Central University of Rajasthan, Bandarsindari 305817 Ajmer, India; [orcid.org/0000-0002-9109-430X](https://orcid.org/0000-0002-9109-430X); Email: [hemant.daima@curaj.ac.in](mailto:hemant.daima@curaj.ac.in)

**Ragini Singh** – Liaocheng University, Shandong 252059, China; Phone: +91 8884774863; Email: [singh@luc.edu.cn](mailto:singh@luc.edu.cn)

### Authors

**Mamta Kumawat** – Department of Biotechnology, School of Sciences, JECRC University, Jaipur 303905 Rajasthan, India

**Himanshu Gogoi** – Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad 121001, India

**Harishkumar Madhyastha** – Department of Cardiovascular Physiology, University of Miyazaki, Miyazaki 8891692, Japan; [orcid.org/0000-0002-7143-4821](https://orcid.org/0000-0002-7143-4821)

**Eric Lichtfouse** – State Key Laboratory of Multiphase Flow in Power Engineering, Xi'an Jiaotong University Xi'an, Shaanxi 710049, China

Complete contact information is available at: <https://pubs.acs.org/10.1021/acsabm.3c00940>

### Notes

The authors declare no competing financial interest.

## ACKNOWLEDGMENTS

R.S. thanks the Natural Science Foundation of Shandong Province (Grant No. ZR2020QC061) and Liaocheng University [318051901]. H.K.D. acknowledges the Centre for Advanced Materials and Industrial Chemistry (CAMIC), School of Sciences, RMIT University, Australia, for an Honorary Visiting Research Fellowship (Sponsorship TRN: EGOE81XKAJ), the Japan Science and Technology (JST) Agency, Japan, for support through the Sakura Exchange Program, and the Central University of Rajasthan, India, for a Seed Grant.

## ABBREVIATIONS

ABP = Azabisphosphonate  
ABZI = Amide benzimidazole  
AgNPs = Silver nanoparticles  
AMPs = Antimicrobial peptide  
APCs = Antigen presenting cells  
AuNPs = Gold nanoparticles  
BAL = Bronchoalveolar lavage  
CCL = C–C motif chemokine ligand  
CCR2 = C–C chemokine receptor type 2  
CeO<sub>2</sub> = Cerium oxide  
CNTs = Carbon nanotubes  
CpG-ODN = CpG oligodeoxynucleotides  
DEX = Dexamethasone  
DNA = Deoxyribonucleic acid  
DTH = Delayed-type hypersensitivity  
EAE = Experimental autoimmune encephalomyelitis  
FACD = Fluorescent aspirin-based carbon dots  
FDA = U.S. Food and Drug Administration

Fe<sub>2</sub>O<sub>3</sub> = Iron oxide  
H&E = Hematoxylin and eosin  
HIF1 $\alpha$  = Hypoxia-inducible factor  
ICAM-1 = Intercellular adhesion molecule-1  
IgE = Immunoglobulin E  
IgG = Immunoglobulin G  
IKK $\beta$  = Inhibitor of nuclear factor kappa-B kinase subunit beta  
IL-1 $\beta$  = Interleukin-1 $\beta$   
JNK = c-Jun N-terminal kinase  
LDH = Lactate dehydrogenase  
LPS = Lipopolysaccharide  
MAPK = Mitogen-activated protein kinase  
MCP-1 = Monocyte chemoattractant protein  
MIP-1 $\alpha$  = Macrophage inflammatory protein-1 $\alpha$   
MN-NLCs = Mannosylated nanostructured lipid carrier system  
NETs = Neutrophil extracellular traps  
NF- $\kappa$ B = Nuclear factor kappa B  
PAMAM = Polyamidoamine  
PBS = Phosphate buffer saline  
PLGA = Poly(lactic-co-glycolic acid)  
QDs = Quantum dots  
ROS = Reactive oxygen species  
SCFA = Short chain fatty acid  
SiO<sub>2</sub> = Silicon dioxide  
siRNA = Small interfering RNA  
STING = Stimulator of interferon genes  
TAK1 = Transforming growth factor- $\beta$ -activated kinase 1  
TNF- $\alpha$  = Tumor necrosis factor-alpha  
Th = T helper  
TiO<sub>2</sub> = Titanium dioxide  
VCAM-1 = Vascular cell adhesion molecule-1  
VEGF = Vascular endothelial growth factor  
ZnO = Zinc oxide

## REFERENCES

- (1) Stater, E. P.; Sonay, A. Y.; Hart, C.; Grimm, J. The ancillary effects of nanoparticles and their implications for nanomedicine. *Nat. Nanotechnol.* **2021**, *16* (11), 1180–1194.
- (2) Eilenberger, C.; Selinger, F.; Rothbauer, M.; Lin, Y.; Limbeck, A.; Schabl, B.; Grillari, J.; Kavok, N. S.; Klochkov, V. K.; Malyukin, Y. V.; Margitich, V.; Ertl, P. Cytotoxicity, retention, and anti-inflammatory effects of a CeO<sub>2</sub> nanoparticle-based supramolecular complex in a 3D liver cell culture model. *ACS Pharmacol. Transl. Sci.* **2021**, *4* (1), 101–106.
- (3) Li, P. Y.; Fan, Z.; Cheng, H. Cell Membrane Bioconjugation and Membrane-Derived Nanomaterials for Immunotherapy. *Bioconjugate Chem.* **2018**, *29* (3), 624–634.
- (4) Edwards, C.; Carey, S. T.; Jewell, C. M. Harnessing Biomaterials to Study and Direct Antigen-Specific Immunotherapy. *ACS Appl. Bio Mater.* **2023**, *6* (6), 2017–2028.
- (5) Huang, Z.; Zhang, X.; Luo, Y.; Wang, Y.; Zhou, S. KCl Nanoparticles as Potential Inducer of Immunogenic Cell Death for Cancer Immunotherapy. *ACS Appl. Bio Mater.* **2023**, *6* (6), 2404–2414.
- (6) Zhang, Q.; Dehaini, D.; Zhang, Y.; Zhou, J.; Chen, X.; Zhang, L.; Fang, R. H.; Gao, W.; Zhang, L. Neutrophil membrane-coated nanoparticles inhibit synovial inflammation and alleviate joint damage in inflammatory arthritis. *Nat. Nanotechnol.* **2018**, *13* (12), 1182–1190.
- (7) Leuschner, F.; Dutta, P.; Gorbatorov, R.; Novobrantseva, T. I.; Donahoe, J. S.; Courties, G.; Lee, K. M.; Kim, J. I.; Markmann, J. F.; Marinelli, B.; Panizzi, P.; Lee, W. W.; Iwamoto, Y.; Milstein, S.; Epstein-Barash, H.; Cantley, W.; Wong, J.; Cortez-Retamozo, V.;

- Newton, A.; Love, K.; Libby, P.; Pittet, M. J.; Swirski, F. K.; Koteliansky, V.; Langer, R.; Weissleder, R.; Anderson, D. G.; Nahrendorf, M. Therapeutic siRNA silencing in inflammatory monocytes in mice. *Nat. Biotechnol.* **2011**, *29* (11), 1005–1010.
- (8) Jia, L. Nanoparticle Formulation Increases Oral Bioavailability of Poorly Soluble Drugs: Approaches Experimental Evidences and Theory. *Curr. Nanosci.* **2005**, *1*, 237–43.
- (9) Farokhzad, O. C.; Cheng, J.; Teply, B. A.; Sherifi, I.; Jon, S.; Kantoff, P. W.; Richie, J. P.; Langer, R. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. *Proc. Natl. Acad. Sci. U S A* **2006**, *103* (16), 6315–6320.
- (10) Emerich, D. F.; Thanos, C. G. Targeted nanoparticle-based drug delivery and diagnosis. *J. Drug Target.* **2007**, *15* (3), 163–183.
- (11) Agemy, L.; Friedmann-Morvinski, D.; Kotamraju, V. R.; Roth, L.; Sugahara, K. N.; Girard, O. M.; Mattrey, R. F.; Verma, I. M.; Ruoslahti, E. Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma. *Proc. Natl. Acad. Sci. U.S.A.* **2011**, *108* (42), 17450–17455.
- (12) Desai, P. P.; Date, A. A.; Patravale, V. B. Overcoming poor oral bioavailability using nanoparticle formulations-opportunities and limitations. *Drug Discovery Today Technol.* **2012**, *9* (2), e87–e95.
- (13) Medina-Reyes, E. I.; Garcia-Viacobo, D.; Carrero-Martinez, F. A.; Chirino, Y. I. Applications and risks of nanomaterials used in regenerative medicine, delivery systems, theranostics, and therapy. *Crit. Rev. Ther. Drug Carrier Syst.* **2017**, *34* (1), 35.
- (14) Sangtani, A.; Nag, O. K.; Field, L. D.; Breger, J. C.; Delehanty, J. B. Multifunctional nanoparticle composites: progress in the use of soft and hard nanoparticles for drug delivery and imaging. *Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.* **2017**, *9* (6), No. e1466.
- (15) Gogoi, H.; Mani, R.; Aggarwal, S.; Malik, A.; Munde, M.; Bhatnagar, R. Crystalline and Amorphous Preparation of Aluminum Hydroxide Nanoparticles Enhances Protective Antigen Domain 4 Specific Immunogenicity and Provides Protection Against Anthrax. *Int. J. Nanomedicine* **2020**, *15*, 239–252.
- (16) Tan, S. L. J.; Billa, N. Improved bioavailability of poorly soluble drugs through gastrointestinal muco-adhesion of lipid nanoparticles. *Pharmaceutics* **2021**, *13* (11), 1817.
- (17) Umapathi, A.; Kumawat, M.; Daima, H. K. Engineered nanomaterials for biomedical applications and their toxicity: a review. *Environ. Chem. Lett.* **2022**, *20* (1), 445–468.
- (18) Dobrovolskaia, M. A.; McNeil, S. E. *Handbook of Immunological Properties of Engineered Nanomaterials (In 3 Volumes)*; World Scientific: 2016; Vol. 6, 1–1184, DOI: 10.1142/9677.
- (19) Dobrovolskaia, M. A.; Shurin, M.; Shvedova, A. A. Current understanding of interactions between nanoparticles and the immune system. *Toxicol. Appl. Pharmacol.* **2016**, *299*, 78–89.
- (20) Aggarwal, P.; Hall, J. B.; McLeland, C. B.; Dobrovolskaia, M. A.; McNeil, S. E. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. *Adv. Drug Delivery Rev.* **2009**, *61* (6), 428–437.
- (21) Liu, Y.; Hardie, J.; Zhang, X.; Rotello, V. M. Effects of Engineered Nanoparticles on the Innate Immune System. *Semin. Immunol.* **2017**, *34*, 25–32.
- (22) Frey, M.; Bobbala, S.; Karabin, N.; Scott, E. Influences of nanocarrier morphology on therapeutic immunomodulation. *Nanomed.* **2018**, *13* (14), 1795–1811.
- (23) Li, Y.; Zhang, X.; Liu, X.; Pan, W.; Li, N.; Tang, B. Designing and Engineering of Nanocarriers for Bioapplication in Cancer Immunotherapy. *ACS Appl. Bio Mater.* **2020**, *3* (12), 8321–8337.
- (24) Seth, A.; Gholami Derami, H.; Gupta, P.; Wang, Z.; Rathi, P.; Gupta, R.; Cao, T.; Morrissey, J. J.; Singamaneni, S. Polydopamine-Mesoporous Silica Core-Shell Nanoparticles for Combined Photothermal Immunotherapy. *ACS Appl. Mater. Interfaces* **2020**, *12* (38), 42499–42510.
- (25) Dobrovolskaia, M. A.; Aggarwal, P.; Hall, J. B.; McNeil, S. E. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. *Mol. Pharmaceutics* **2008**, *5* (4), 487–495.
- (26) Naahidi, S.; Jafari, M.; Edalat, F.; Raymond, K.; Khademhosseini, A.; Chen, P. Biocompatibility of engineered nanoparticles for drug delivery. *J. Controlled Release* **2013**, *166* (2), 182–194.
- (27) Manke, A.; Wang, L.; Rojanasakul, Y. Mechanisms of nanoparticle-induced oxidative stress and toxicity. *Biomed Res. Int.* **2013**, *2013*, 1.
- (28) Lenders, V.; Koutsoumpou, X.; Sargsian, A.; Manshian, B. B. Biomedical nanomaterials for immunological applications: ongoing research and clinical trials. *Nanoscale Adv.* **2020**, *2* (11), S046–S089.
- (29) Chen, L.; Glass, J. J.; De Rose, R.; Sperling, C.; Kent, S. J.; Houston, Z. H.; Fletcher, N. L.; Rolfe, B. E.; Thurecht, K. J. Influence of Charge on Hemocompatibility and Immunoreactivity of Polymeric Nanoparticles. *ACS Appl. Bio Mater.* **2018**, *1* (3), 756–767.
- (30) Bahreyni, A.; Mohamud, Y.; Luo, H. Emerging nanomedicines for effective breast cancer immunotherapy. *J. Nanobiotechnology* **2020**, *18* (1), 1–14.
- (31) Cai, T.; Liu, H.; Zhang, S.; Hu, J.; Zhang, L. Delivery of nanovaccine towards lymphoid organs: recent strategies in enhancing cancer immunotherapy. *J. Nanobiotechnology* **2021**, *19* (1), 1–23.
- (32) Liu, Z.; Xie, Z.; Li, W.; Wu, X.; Jiang, X.; Li, G.; Cao, L.; Zhang, D.; Wang, Q.; Xue, P.; Zhang, H. Photodynamic immunotherapy of cancers based on nanotechnology: recent advances and future challenges. *J. Nanobiotechnology* **2021**, *19* (1), 1–18.
- (33) Feldman, E. J.; Lancet, J. E.; Koltz, J. E.; Ritchie, E. K.; Roboz, G. J.; List, A. F.; Allen, S. L.; Asatiani, E.; Mayer, L. D.; Swenson, C.; Louie, A. C. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. *J. Clin. Oncol.* **2011**, *29* (8), 979.
- (34) Banerjee, K.; Wang, Q.; Wang, J.; Gibbons, J. CPX-351 exposure-response based on cumulative dose of cytarabine and daunorubicin in patients with newly diagnosed, treatment-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes. *Blood* **2017**, *130*, 1360.
- (35) Bonvalot, S.; Le Pechoux, C.; De Baere, T.; Kantor, G.; Buy, X.; Stoeckle, E.; Terrier, P.; Sargos, P.; Coindre, J. M.; Lassau, N.; Ait Sarkouh, R.; Dimitriu, M.; Borghi, E.; Levy, L.; Deutsch, E.; Soria, J.-C. First-in-human study testing a new radioenhancer using nanoparticles (NBTXR3) activated by radiation therapy in patients with locally advanced soft tissue sarcomas. *Clin. Cancer Res.* **2017**, *23* (4), 908–917.
- (36) Bonvalot, S.; Rutkowski, P. L.; Thariat, J.; Carrere, S.; Ducassou, A.; Sunyach, M.-P.; Agoston, P.; Hong, A.; Mervoyer, A.; Rastrelli, M.; Moreno, V.; Li, R. K.; Tiangco, B.; Herraes, A. C.; Gronchi, A.; Mangel, L.; Sy-Ortin, T.; Hohenberger, P.; de Baere, T.; Le Cesne, A.; Helfre, S.; Saada-Bouazid, E.; Borkowska, A.; Anghel, R.; Co, A.; Gebhart, M.; Kantor, G.; Montero, A.; Loong, H. H.; Verges, R.; Lapeire, L.; Dema, S.; Kacso, G.; Austen, L.; Moureau-Zabotto, L.; Servois, V.; Wardelmann, E.; Terrier, P.; Lazar, A. J.; Bovee, J. V M G; Le Pechoux, C.; Papai, Z. NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act. In. Sarc): a multicentre, phase 2–3, randomised, controlled trial. *Lancet Oncol.* **2019**, *20* (8), 1148–1159.
- (37) Baden, L. R.; El Sahly, H. M.; Essink, B.; Kotloff, K.; Frey, S.; Novak, R.; Diemert, D.; Spector, S. A.; Rouphael, N.; Creech, C. B.; McGettigan, J.; Khetan, S.; Segall, N.; Solis, J.; Brosz, A.; Fierro, C.; Schwartz, H.; Neuzil, K.; Corey, L.; Gilbert, P.; Janes, H.; Follmann, D.; Marovich, M.; Mascola, J.; Polakowski, L.; Ledgerwood, J.; Graham, B. S.; Bennett, H.; Pajon, R.; Knightly, C.; Leav, B.; Deng, W.; Zhou, H.; Han, S.; Ivarsson, M.; Miller, J.; Zaks, T. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J. Med.* **2021**, *384* (5), 403–416.
- (38) Park, J. W.; Lagniton, P. N. P.; Liu, Y.; Xu, R. H. mRNA vaccines for COVID-19: what, why and how. *Int. J. Biol. Sci.* **2021**, *17* (6), 1446–1460.
- (39) Thomas, S. J.; Moreira, E. D.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Perez, J. L.; Perez Marc, G.; Polack, F. P.;

- Zerbini, C.; Bailey, R.; Swanson, K. A.; Xu, X.; Roychoudhury, S.; Koury, K.; Bouguermouh, S.; Kalina, W. V.; Cooper, D.; Frenck, R. W.; Hammitt, L. L.; Tureci, O.; Nell, H.; Schaefer, A.; Unal, S.; Yang, Q.; Liberato, P.; Tresnan, D. B.; Mather, S.; Dormitzer, P. R.; Sahin, U.; Gruber, W. C.; Jansen, K. U. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. *N. Engl. J. Med.* **2021**, *385* (19), 1761–1773.
- (40) Fang, E.; Liu, X.; Li, M.; Zhang, Z.; Song, L.; Zhu, B.; Wu, X.; Liu, J.; Zhao, D.; Li, Y. Advances in COVID-19 mRNA vaccine development. *Signal Transduct. Target. Ther.* **2022**, *7* (1), 94.
- (41) Boswell, G.; Buell, D.; Bekersky, I. AmBisome (liposomal amphotericin B): a comparative review. *J. Clin. Pharmacol.* **1998**, *38* (7), S83–S92.
- (42) Tollemar, J.; Klingspor, L.; Ringden, O. Liposomal amphotericin B (AmBisome) for fungal infections in immunocompromised adults and children. *Clin. Microbiol. Infect.* **2001**, *7*, 68–79.
- (43) Fassas, A.; Buffels, R.; Anagnostopoulos, A.; Gacos, E.; Vadikolia, C.; Haloudis, P.; Kaloyannidis, P. J. B. j. o. h. Safety and early efficacy assessment of liposomal daunorubicin (DaunoXome) in adults with refractory or relapsed acute myeloblastic leukaemia: a phase I-II study. *Br. J. Haematol.* **2002**, *116* (2), 308–315.
- (44) Andreopoulou, E.; Gaiotti, D.; Kim, E.; Downey, A.; Mirchandani, D.; Hamilton, A.; Jacobs, A.; Curtin, J.; Muggia, F. Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil®): Experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer. *Ann. Oncol.* **2007**, *18* (4), 716–721.
- (45) Baribeault, D. Sodium ferric gluconate (SFG) in complex with sucrose for IV infusion: bioequivalence of a new generic product with the branded product in healthy volunteers. *Curr. Med. Res. Opin.* **2011**, *27* (8), 1653–1657.
- (46) Wang, Y.-X. J. Current status of superparamagnetic iron oxide contrast agents for liver magnetic resonance imaging. *World J. Gastroenterol.* **2015**, *21* (47), 13400.
- (47) Zhang, H. Onivyde for the therapy of multiple solid tumors. *OncoTargets Ther.* **2016**, 3001–3007.
- (48) Macdougall, I. C.; Comin-Colet, J.; Breymann, C.; Spahn, D. R.; Koutroubakis, I. E. Iron sucrose: A wealth of experience in treating iron deficiency. *Adv. Ther.* **2020**, *37*, 1960–2002.
- (49) Hagens, W. I.; Oomen, A. G.; de Jong, W. H.; Cassee, F. R.; Sips, A. J. What do we (need to) know about the kinetic properties of nanoparticles in the body? *Regula. toxicol. pharmacol.* **2007**, *49* (3), 217–229.
- (50) Bahadar, H.; Maqbool, F.; Niaz, K.; Abdollahi, M. Toxicity of nanoparticles and an overview of current experimental models. *Iran. Biomed. J.* **2016**, *20* (1), 1–11.
- (51) Ispas, C.; Andreescu, D.; Patel, A.; Goia, D. V.; Andreescu, S.; Wallace, K. N. Toxicity and developmental defects of different sizes and shape nickel nanoparticles in zebrafish. *Environ. Sci. Technol.* **2009**, *43* (16), 6349–6356.
- (52) Andersson, P. O.; Lejon, C.; Ekstrand-Hammarström, B.; Akfur, C.; Ahlinder, L.; Bucht, A.; Österlund, L. Polymorph- and size-dependent uptake and toxicity of TiO<sub>2</sub> nanoparticles in living lung epithelial cells. *Small* **2011**, *7* (4), 514–523.
- (53) El Badawy, A. M.; Silva, R. G.; Morris, B.; Scheckel, K. G.; Suidan, M. T.; Tolaymat, T. M. Surface charge-dependent toxicity of silver nanoparticles. *Environ. Sci. Technol.* **2011**, *45* (1), 283–287.
- (54) Schaeublin, N. M.; Braydich-Stolle, L. K.; Schrand, A. M.; Miller, J. M.; Hutchison, J.; Schlager, J. J.; Hussain, S. M. Surface charge of gold nanoparticles mediates mechanism of toxicity. *Nanoscale* **2011**, *3* (2), 410–420.
- (55) Zhao, X.; Ng, S.; Heng, B. C.; Guo, J.; Ma, L.; Tan, T. T. Y.; Ng, K. W.; Loo, S. C. J. Cytotoxicity of hydroxyapatite nanoparticles is shape and cell dependent. *Arch. Toxicol.* **2013**, *87*, 1037–1052.
- (56) Pan, Y.; Neuss, S.; Leifert, A.; Fischler, M.; Wen, F.; Simon, U.; Schmid, G.; Brandau, W.; Jahnen-Dechent, W. Size-dependent cytotoxicity of gold nanoparticles. *Small* **2007**, *3* (11), 1941–9.
- (57) Wang, F.; Bexiga, M. G.; Anguissola, S.; Boya, P.; Simpson, J. C.; Salvati, A.; Dawson, K. A. Time resolved study of cell death mechanisms induced by amine-modified polystyrene nanoparticles. *Nanoscale* **2013**, *5* (22), 10868–10876.
- (58) Ghooshchian, M.; Khodarahmi, P.; Tafvizi, F. Apoptosis-mediated neurotoxicity and altered gene expression induced by silver nanoparticles. *Toxicol. Ind. Health.* **2017**, *33* (10), 757–764.
- (59) Niu, Y.; Tang, E.; Zhang, Q. J. T. r. Cytotoxic effect of silica nanoparticles against hepatocellular carcinoma cells through necrosis induction. *Toxicol. Res.* **2019**, *8* (6), 1042–1049.
- (60) Yin, S.; Liu, J.; Kang, Y.; Lin, Y.; Li, D.; Shao, L. Interactions of nanomaterials with ion channels and related mechanisms. *Br. J. Pharmacol.* **2019**, *176* (19), 3754–3774.
- (61) Foreman-Ortiz, I. U.; Liang, D.; Laudadio, E. D.; Calderin, J. D.; Wu, M.; Keshri, P.; Zhang, X.; Schwartz, M. P.; Hamers, R. J.; Rotello, V. M.; Murphy, C. J.; Cui, Q.; Pedersen, J. A. Anionic nanoparticle-induced perturbation to phospholipid membranes affects ion channel function. *Proc. Natl. Acad. Sci. U S A* **2020**, *117* (45), 27854–27861.
- (62) Fu, P. P.; Xia, Q.; Hwang, H. M.; Ray, P. C.; Yu, H. Mechanisms of nanotoxicity: generation of reactive oxygen species. *J. Food Drug Anal.* **2014**, *22* (1), 64–75.
- (63) Müller, R.; Runge, S.; Ravelli, V.; Thünemann, A. F.; Mehnert, W.; Souto, E. Cyclosporine-loaded solid lipid nanoparticles (SLN®): Drug-lipid physicochemical interactions and characterization of drug incorporation. *Eur. J. Pharm. Biopharm.* **2008**, *68* (3), 535–544.
- (64) Rouf, M. A.; Vural, I.; Renoir, J. M.; Hincal, A. A. Development and characterization of liposomal formulations for rapamycin delivery and investigation of their antiproliferative effect on MCF7 cells. *J. Liposome Res.* **2009**, *19* (4), 322–331.
- (65) Pople, P. V.; Singh, K. K. Targeting tacrolimus to deeper layers of skin with improved safety for treatment of atopic dermatitis—Part II: In vivo assessment of dermatopharmacokinetics, biodistribution and efficacy. *Int. J. Pharm.* **2012**, *434* (1–2), 70–79.
- (66) Tammam, S.; Mathur, S.; Afifi, N. Preparation and biopharmaceutical evaluation of tacrolimus loaded biodegradable nanoparticles for liver targeting. *J. Biomed Nanotechnol.* **2012**, *8* (3), 439–449.
- (67) Tang, L.; Azzi, J.; Kwon, M.; Mounayar, M.; Tong, R.; Yin, Q.; Moore, R.; Skartsis, N.; Fan, T. M.; Abdi, R.; Cheng, J. Immunosuppressive activity of size-controlled PEG-PLGA nanoparticles containing encapsulated cyclosporine A. *J. Transplant.* **2012**, *2012*, 1–9.
- (68) Shah, M.; Edman, M. C.; Janga, S. R.; Shi, P.; Dhandhukia, J.; Liu, S.; Louie, S. G.; Rodgers, K.; MacKay, J. A.; Hamm-Alvarez, S. F. A rapamycin-binding protein polymer nanoparticle shows potent therapeutic activity in suppressing autoimmune dacryoadenitis in a mouse model of Sjögren's syndrome. *J. Controlled Release* **2013**, *171* (3), 269–279.
- (69) Mitchell, L.; Lauer, F.; Burchiel, S.; McDonald, J. Mechanisms for how inhaled multiwalled carbon nanotubes suppress systemic immune function in mice. *Nat. Nanotechnol.* **2009**, *4* (7), 451–456.
- (70) Shen, C.-C.; Liang, H.-J.; Wang, C.-C.; Liao, M.-H.; Jan, T.-R. Iron oxide nanoparticles suppressed T helper 1 cell-mediated immunity in a murine model of delayed-type hypersensitivity. *Int. J. Nanomedicine* **2012**, 2729–2737.
- (71) Tsai, C.-Y.; Lu, S.-L.; Hu, C.-W.; Yeh, C.-S.; Lee, G.-B.; Lei, H.-Y. Size-dependent attenuation of TLR9 signaling by gold nanoparticles in macrophages. *J. Immun.* **2012**, *188* (1), 68–76.
- (72) Ding, N.; Kunugita, N.; Ichinose, T.; Song, Y.; Yokoyama, M.; Arashidani, K.; Yoshida, Y. Intratracheal administration of fullerene nanoparticles activates splenic CD11b+ cells. *J. Hazard. Mater.* **2011**, *194*, 324–330.
- (73) Srinivas, A.; Rao, P. J.; Selvam, G.; Murthy, P. B.; Reddy, P. N. Acute inhalation toxicity of cerium oxide nanoparticles in rats. *Toxicol. Lett.* **2011**, *205* (2), 105–115.
- (74) Aalapati, S.; Ganapathy, S.; Manapuram, S.; Anumolu, G.; Prakya, B. M. Toxicity and bio-accumulation of inhaled cerium oxide nanoparticles in CD1 mice. *Nanotoxicology* **2014**, *8* (7), 786–798.
- (75) Zhang, W.; Cao, S.; Liang, S.; Tan, C. H.; Luo, B.; Xu, X.; Saw, P. E. Differently charged super-paramagnetic iron oxide nanoparticles

- preferentially induced M1-like phenotype of macrophages. *Front. Bioeng. Biotechnol.* **2020**, *8*, 537.
- (76) Saafane, A.; Girard, D. Interaction between iron oxide nanoparticles (Fe<sub>3</sub>O<sub>4</sub> NPs) and human neutrophils: Evidence that Fe<sub>3</sub>O<sub>4</sub> NPs possess some pro-inflammatory activities. *Chem. Biol. Interact.* **2022**, *365*, 110053.
- (77) Boraschi, D.; Costantino, L.; Italiani, P. J. N. Interaction of nanoparticles with immunocompetent cells: nanosafety considerations. *Nanomed.* **2012**, *7* (1), 121–131.
- (78) Elsabahy, M.; Wooley, K. L. Cytokines as biomarkers of nanoparticle immunotoxicity. *Chem. Soc. Rev.* **2013**, *42* (12), 5552–5576.
- (79) Muhammad, Q.; Jang, Y.; Kang, S. H.; Moon, J.; Kim, W. J.; Park, H. Modulation of immune responses with nanoparticles and reduction of their immunotoxicity. *Biomater. Sci.* **2020**, *8* (6), 1490–1501.
- (80) Sakai, T.; Kohno, H.; Ishihara, T.; Higaki, M.; Saito, S.; Matsushima, M.; Mizushima, Y.; Kitahara, K. Treatment of experimental autoimmune uveoretinitis with poly (lactic acid) nanoparticles encapsulating betamethasone phosphate. *Exp. Eye Res.* **2006**, *82* (4), 657–663.
- (81) Ferreira, S. A.; Gama, F. M.; Vilanova, M. Polymeric nanogels as vaccine delivery systems. *Nanomedicine: NBM* **2013**, *9* (2), 159–173.
- (82) Boraschi, D.; Italiani, P.; Palomba, R.; Decuzzi, P.; Duschl, A.; Fadeel, B.; Moghimi, S. M. Nanoparticles and Innate Immunity: New Perspectives on Host Defence. *Semin. Immunol.* **2017**, *34*, 33–51.
- (83) Broz, P.; Dixit, V. M. Inflammasomes: mechanism of assembly, regulation and signalling. *Nat. Rev. Immunol.* **2016**, *16* (7), 407–420.
- (84) Fytianos, K.; Rodriguez-Lorenzo, L.; Clift, M. J.; Blank, F.; Vanhecke, D.; Von Garnier, C.; Petri-Fink, A.; Rothen-Rutishauser, B. J. N. N. Biology; Medicine. Uptake efficiency of surface modified gold nanoparticles does not correlate with functional changes and cytokine secretion in human dendritic cells in vitro. *Nanomedicine: NBM* **2015**, *11* (3), 633–644.
- (85) Tang, M.; Li, S.; Wei, L.; Hou, Z.; Qu, J.; Li, L. Do engineered nanomaterials affect immune responses by interacting with gut microbiota? *Front. Immunol.* **2021**, *12*, 684605.
- (86) Zhang, Y.-Z.; Li, Y.-Y. Inflammatory bowel disease: pathogenesis. *World J. Gastroenterol.* **2014**, *20* (1), 91.
- (87) Chen, H.; Zhao, R.; Wang, B.; Zheng, L.; Ouyang, H.; Wang, H.; Zhou, X.; Zhang, D.; Chai, Z.; Zhao, Y.; Feng, W. Acute Oral Administration of Single-Walled Carbon Nanotubes Increases Intestinal Permeability and Inflammatory Responses: Association with the Changes in Gut Microbiota in Mice. *Adv. Healthc. Mater.* **2018**, *7* (13), 1701313.
- (88) Ozbakir, B.; Crielgaard, B. J.; Metselaar, J. M.; Storm, G.; Lammers, T. Liposomal corticosteroids for the treatment of inflammatory disorders and cancer. *J. Controlled Release* **2014**, *190*, 624–636.
- (89) Alaarg, A.; Perez-Medina, C.; Metselaar, J. M.; Nahrendorf, M.; Fayad, Z. A.; Storm, G.; Mulder, W. J. Applying nanomedicine in maladaptive inflammation and angiogenesis. *Adv. Drug Delivery Rev.* **2017**, *119*, 143–158.
- (90) Qi, D.; Wei, M.; Jiao, S.; Song, Y.; Wang, X.; Xie, G.; Taranto, J.; Liu, Y.; Duan, Y.; Yu, B.; Li, H.; Shah, Y. M.; Xu, Q.; Du, J.; Gonzalez, F. J.; Qu, A. Hypoxia inducible factor 1alpha in vascular smooth muscle cells promotes angiotensin II-induced vascular remodeling via activation of CCL7-mediated macrophage recruitment. *Cell Death Dis.* **2019**, *10*, 544.
- (91) Mishra, V.; Prajapati, G.; Baranwal, V.; Mishra, R. K. NMR-Based Metabolomic Imprinting Elucidates Macrophage Polarization of THP-1 Cell Lines Stimulated by Zinc Oxide Nanoparticles. *ACS Appl. Bio Mater.* **2022**, *5* (10), 4873–4885.
- (92) Park, J.; Zhang, Y.; Saito, E.; Gurczynski, S. J.; Moore, B. B.; Cummings, B. J.; Anderson, A. J.; Shea, L. D. Intravascular innate immune cells reprogrammed via intravenous nanoparticles to promote functional recovery after spinal cord injury. *Proc. Natl. Acad. Sci. U S A* **2019**, *116* (30), 14947–14954.
- (93) Fang, R. H.; Kroll, A. V.; Gao, W.; Zhang, L. Cell membrane coating nanotechnology. *Adv. Mater.* **2018**, *30* (23), 1706759.
- (94) Colon, D. F.; Wanderley, C. W.; Franchin, M.; Silva, C. M.; Hiroki, C. H.; Castanheira, F. V. S.; Donate, P. B.; Lopes, A. H.; Volpon, L. C.; Kavaguti, S. K.; Borges, V. F.; Speck-Hernandez, C. A.; Ramalho, F.; Carlotti, A. P.; Carmona, F.; Alves-Filho, J. C.; Liew, F. Y.; Cunha, F. Q. Neutrophil extracellular traps (NETs) exacerbate severity of infant sepsis. *Crit. Care.* **2019**, *23* (1), 1–13.
- (95) Mehta, P.; McAuley, D. F.; Brown, M.; Sanchez, E.; Tattersall, R. S.; Manson, J. J. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet* **2020**, *395* (10229), 1033–1034.
- (96) Lee, Y. Y.; Park, H. H.; Park, W.; Kim, H.; Jang, J. G.; Hong, K. S.; Lee, J.-Y.; Seo, H. S.; Na, D. H.; Kim, T.-H.; Choy, Y. B.; Ahn, J. H.; Lee, W.; Park, C. G. Long-acting nanoparticulate DNase-1 for effective suppression of SARS-CoV-2-mediated neutrophil activities and cytokine storm. *Biomater.* **2021**, *267*, 120389.
- (97) Smarr, C. B.; Yap, W. T.; Neef, T. P.; Pearson, R. M.; Hunter, Z. N.; Ifergan, I.; Getts, D. R.; Bryce, P. J.; Shea, L. D.; Miller, S. D. Biodegradable antigen-associated PLG nanoparticles tolerate Th2-mediated allergic airway inflammation pre-and postsensitization. *Proc. Natl. Acad. Sci. U S A* **2016**, *113* (18), 5059–5064.
- (98) Wu, Y.; Shi, W.; Wang, H.; Yue, J.; Mao, Y.; Zhou, W.; Kong, X.; Guo, Q.; Zhang, L.; Xu, P.; Wang, Y. Anti-ST2 Nanoparticle Alleviates Lung Inflammation by Targeting ILC2s-CD4+ T Response. *Int. J. Nanomedicine* **2020**, *15*, 9745–9758.
- (99) Ozcan, A.; Sahin, D.; Impellizzeri, D.; Nguyen, T. T.; Hafner, J.; Yawalkar, N.; Kurzbach, D.; Tan, G.; Akdis, C. A.; Nilsson, J.; Boyman, O.; Kolios, A. G. A. Nanoparticle-coupled topical methotrexate can normalize immune responses and induce tissue remodeling in psoriasis. *J. Invest. Dermatol.* **2020**, *140* (5), 1003–1014.
- (100) Liu, J.; Liu, Z.; Pang, Y.; Zhou, H. The interaction between nanoparticles and immune system: Application in the treatment of inflammatory diseases. *J. Nanobiotechnology* **2022**, *20* (1), 1–25.
- (101) Liu, R.; Zhang, X.; Pu, Y.; Yin, L.; Li, Y.; Zhang, X.; Liang, G.; Li, X.; Zhang, J. Small-sized titanium dioxide nanoparticles mediate immune toxicity in rat pulmonary alveolar macrophages in vivo. *J. Nanosci. Nanotechnol.* **2010**, *10* (8), 5161–5169.
- (102) Song, W.-J.; Jeong, M.-S.; Choi, D.-M.; Kim, K.-N.; Wie, M.-B. Zinc oxide nanoparticles induce autophagy and apoptosis via oxidative injury and pro-inflammatory cytokines in primary astrocyte cultures. *Nanomaterials* **2019**, *9* (7), 1043.
- (103) Müller, K.; Skepper, J. N.; Posfai, M.; Trivedi, R.; Howarth, S.; Corot, C.; Lancelot, E.; Thompson, P. W.; Brown, A. P.; Gillard, J. Effect of ultrasmall superparamagnetic iron oxide nanoparticles (Ferumoxtran-10) on human monocyte-macrophages in vitro. *Biomater.* **2007**, *28* (9), 1629–1642.
- (104) Clemente-Casares, X.; Blanco, J.; Ambalavanan, P.; Yamanouchi, J.; Singha, S.; Fandos, C.; Tsai, S.; Wang, J.; Garabatos, N.; Izquierdo, C.; Agrawal, S.; Keough, M. B.; Yong, V. W.; James, E.; Moore, A.; Yang, Y.; Stratmann, T.; Serra, P.; Santamaria, P. Expanding antigen-specific regulatory networks to treat autoimmunity. *Nature* **2016**, *530* (7591), 434–440.
- (105) Wolf-Grosse, S.; Rokstad, A. M.; Ali, S.; Lambris, J. D.; Mollnes, T. E.; Nilsen, A. M.; Stenvik, J. Iron oxide nanoparticles induce cytokine secretion in a complement-dependent manner in a human whole blood model. *Int. J. Nanomedicine* **2017**, *12*, 3927.
- (106) Kwon, D.; Cha, B. G.; Cho, Y.; Min, J.; Park, E.-B.; Kang, S.-J.; Kim, J. Extra-large pore mesoporous silica nanoparticles for directing in vivo M2 macrophage polarization by delivering IL-4. *Nano Lett.* **2017**, *17* (5), 2747–2756.
- (107) Taratumarat, S.; Sangphech, N.; Vu, C. T. B.; Palaga, T.; Ondee, T.; Surawut, S.; Sereemasapun, A.; Ritprajak, P.; Leelahavanichkul, A. Gold nanoparticles attenuates bacterial sepsis in cecal ligation and puncture mouse model through the induction of M2 macrophage polarization. *BMC Microbiol.* **2018**, *18* (1), 1–10.
- (108) Fujita, T.; Zysman, M.; Elgrabli, D.; Murayama, T.; Haruta, M.; Lanone, S.; Ishida, T.; Boczkowski, J. Anti-inflammatory effect of

- gold nanoparticles supported on metal oxides. *Sci. Rep.* **2021**, *11* (1), 23129.
- (109) Koushki, K.; Keshavarz Shahbaz, S.; Keshavarz, M.; Bezsonov, E. E.; Sathyapalan, T.; Sahebkar, A. J. B. Gold nanoparticles: Multifaceted roles in the management of autoimmune disorders. *Biomolecules* **2021**, *11* (9), 1289.
- (110) Li, W.-T.; Chang, H.-W.; Yang, W.-C.; Lo, C.; Wang, L.-Y.; Pang, V. F.; Chen, M.-H.; Jeng, C.-R. Immunotoxicity of silver nanoparticles (AgNPs) on the leukocytes of common bottlenose dolphins (*Tursiops truncatus*). *Sci. Rep.* **2018**, *8* (1), 5593.
- (111) Nygaard, U. C.; Hansen, J. S.; Samuelsen, M.; Alberg, T.; Marioara, C. D.; Løvik, M. Single-walled and multi-walled carbon nanotubes promote allergic immune responses in mice. *Toxicol. Sci.* **2009**, *109* (1), 113–123.
- (112) Wang, X.; Podila, R.; Shannahan, J. H.; Rao, A. M.; Brown, J. M. Intravenously delivered graphene nanosheets and multiwalled carbon nanotubes induce site-specific Th2 inflammatory responses via the IL-33/ST2 axis. *Int. J. Nanomedicine* **2013**, 1733–1748.
- (113) Nguyen, K. C.; Seligy, V. L.; Tayabali, A. F. Cadmium telluride quantum dot nanoparticle cytotoxicity and effects on model immune responses to *Pseudomonas aeruginosa*. *Nanotoxicology* **2013**, *7* (2), 202–211.
- (114) Krohn-Grimberghe, M.; Mitchell, M. J.; Schloss, M. J.; Khan, O. F.; Courties, G.; Guimaraes, P. P. G.; Rohde, D.; Cremer, S.; Kowalski, P. S.; Sun, Y.; Tan, M.; Webster, J.; Wang, K.; Iwamoto, Y.; Schmidt, S. P.; Wojtkiewicz, G. R.; Nayar, R.; Frodermann, V.; Hulsmans, M.; Chung, A.; Hoyer, F. F.; Swirski, F. K.; Langer, R.; Anderson, D. G.; Nahrendorf, M. Nanoparticle-encapsulated siRNAs for gene silencing in the haematopoietic stem-cell niche. *Nat. Biomed. Eng.* **2020**, *4* (11), 1076–1089.
- (115) Bacci, M.; Capobianco, A.; Monno, A.; Cottone, L.; Di Puppo, F.; Camisa, B.; Mariani, M.; Brignole, C.; Ponzoni, M.; Ferrari, S.; Panina-Bordignon, P.; Manfredi, A. A.; Rovere-Querini, P. Macrophages are alternatively activated in patients with endometriosis and required for growth and vascularization of lesions in a mouse model of disease. *Am. J. Pathol.* **2009**, *175* (2), 547–556.
- (116) Thamphiwatana, S.; Angsantikul, P.; Escajadillo, T.; Zhang, Q.; Olson, J.; Luk, B. T.; Zhang, S.; Fang, R. H.; Gao, W.; Nizet, V.; Zhang, L. Macrophage-like nanoparticles concurrently absorbing endotoxins and proinflammatory cytokines for sepsis management. *Proc. Natl. Acad. Sci. U S A* **2017**, *114* (43), 11488–11493.
- (117) Pereira, M.; Francisco, S.; Varanda, A. S.; Santos, M.; Santos, M. A.; Soares, A. R. Impact of tRNA modifications and tRNA-modifying enzymes on proteostasis and human disease. *Int. J. Mol. Sci.* **2018**, *19* (12), 3738.
- (118) Liu, Y.; Ai, K.; Ji, X.; Askhatova, D.; Du, R.; Lu, L.; Shi, J. Comprehensive insights into the multi-antioxidative mechanisms of melanin nanoparticles and their application to protect brain from injury in ischemic stroke. *J. Am. Chem. Soc.* **2017**, *139* (2), 856–862.
- (119) Zhong, G.; Yang, X.; Jiang, X.; Kumar, A.; Long, H.; Xie, J.; Zheng, L.; Zhao, J. Dopamine-melanin nanoparticles scavenge reactive oxygen and nitrogen species and activate autophagy for osteoarthritis therapy. *Nanoscale* **2019**, *11* (24), 11605–11616.
- (120) Liu, J.-H.; Ma, X.; Xu, Y.; Tang, H.; Yang, S.-T.; Yang, Y.-F.; Kang, D.-D.; Wang, H.; Liu, Y. Low toxicity and accumulation of zinc oxide nanoparticles in mice after 270-day consecutive dietary supplementation. *Toxicol. Res.* **2017**, *6* (2), 134–143.
- (121) Ngobili, T. A.; Daniele, M. A. J. E. b. medicine. Nanoparticles and direct immunosuppression. *Exp. Biol. Med.* **2016**, *241* (10), 1064–1073.
- (122) García-Álvarez, R.; Hadjidemetriou, M.; Sánchez-Iglesias, A.; Liz-Marzán, L. M.; Kostarelos, K. In vivo formation of protein corona on gold nanoparticles. The effect of their size and shape. *Nanoscale* **2018**, *10* (3), 1256–1264.
- (123) Padmanabhan, J.; Kyriakides, T. R. Nanomaterials, inflammation, and tissue engineering. *Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.* **2015**, *7* (3), 355–370.
- (124) Kumawat, M.; Madhyashta, H.; Singh, M.; Revaprasadu, N.; Srinivas, S. P.; Daima, H. K. Double functionalized haemocompatible silver nanoparticles control cell inflammatory homeostasis. *PLoS one* **2022**, *17* (10), No. e0276296.
- (125) Muller, L.; Riediker, M.; Wick, P.; Mohr, M.; Gehr, P.; Rothen-Rutishauser, B. Oxidative stress and inflammation response after nanoparticle exposure: differences between human lung cell monocultures and an advanced three-dimensional model of the human epithelial airways. *J. R. Soc. Interface* **2010**, *7*, S27–S40.
- (126) Ilinskaya, A.; Dobrovolskaia, M. Immunosuppressive and anti-inflammatory properties of engineered nanomaterials. *Br. J. Pharmacol.* **2014**, *171* (17), 3988–4000.
- (127) Lin, J. B.; Poh, S.; Panitch, A. Controlled release of anti-inflammatory peptides from reducible thermosensitive nanoparticles suppresses cartilage inflammation. *Nanomedicine: NBM* **2016**, *12* (7), 2095–2100.
- (128) Brusini, R.; Varna, M.; Couvreur, P. Advanced nanomedicines for the treatment of inflammatory diseases. *Adv. Drug Delivery Rev.* **2020**, *157*, 161–178.
- (129) Chang, M.-C.; Kuo, Y.-J.; Hung, K.-H.; Peng, C.-L.; Chen, K.-Y.; Yeh, L.-K. Liposomal dexamethasone-moxifloxacin nanoparticle combinations with collagen/gelatin/alginate hydrogel for corneal infection treatment and wound healing. *Biomed. Mater.* **2020**, *15* (5), 055022.
- (130) Raimondo, T. M.; Mooney, D. J. Anti-inflammatory nanoparticles significantly improve muscle function in a murine model of advanced muscular dystrophy. *Sci. Adv.* **2021**, *7* (26), No. eabh3693.
- (131) Browne, S.; Pandit, A. Biomaterial-mediated modification of the local inflammatory environment. *Front. bioeng. biotechnol.* **2015**, *3*, 67.
- (132) Wang, H.; Zhou, Y.; Sun, Q.; Zhou, C.; Hu, S.; Lenahan, C.; Xu, W.; Deng, Y.; Li, G.; Tao, S. Update on nanoparticle-based drug delivery system for anti-inflammatory treatment. *Front. Bioeng. Biotechnol.* **2021**, *9*, 630352.
- (133) Li, Q.; Chen, Q.; Yang, X.; Zhang, Y.; Lv, L.; Zhang, Z.; Zeng, S.; Lv, J.; Liu, S.; Fu, B. Cocktail strategy based on a dual function nanoparticle and immune activator for effective tumor suppressive. *J. Nanobiotechnology* **2022**, *20* (1), 84.
- (134) Anderson, R.; Franch, A.; Castell, M.; Perez-Cano, F. J.; Brauer, R.; Pohlers, D.; Gajda, M.; Siskos, A. P.; Katsila, T.; Tamvakopoulos, C.; Rauchhaus, U.; Panzner, S.; Kinne, R. W. Liposomal encapsulation enhances and prolongs the anti-inflammatory effects of water-soluble dexamethasone phosphate in experimental adjuvant arthritis. *Arthritis Res. Ther.* **2010**, *12* (4), R147.
- (135) Ferreira-Silva, M.; Faria-Silva, C.; Viana Baptista, P.; Fernandes, E.; Ramos Fernandes, A.; Corvo, M. L. Liposomal nanosystems in rheumatoid arthritis. *Pharmaceutics* **2021**, *13* (4), 454.
- (136) Toita, R.; Kawano, T.; Murata, M.; Kang, J.-H. Anti-obesity and anti-inflammatory effects of macrophage-targeted interleukin-10-conjugated liposomes in obese mice. *Biomater.* **2016**, *110*, 81–88.
- (137) Xie, Y.; Papadopoulou, P.; de Wit, B.; d'Engelbronner, J. C.; van Hage, P.; Kros, A.; Schaaf, M. J. Two types of liposomal formulations improve the therapeutic ratio of prednisolone phosphate in a zebrafish model for inflammation. *Cells* **2022**, *11* (4), 671.
- (138) Hayder, M.; Poupot, M.; Baron, M.; Nigon, D.; Turrin, C.-O.; Caminade, A.-M.; Majoral, J.-P.; Eisenberg, R. A.; Fournie, J.-J.; Cantagrel, A.; Poupot, R.; Davignon, J.-L. A phosphorus-based dendrimer targets inflammation and osteoclastogenesis in experimental arthritis. *Sci. Transl. Med.* **2011**, *3* (81), 81ra35–81ra35.
- (139) Blattes, E.; Vercellone, A.; Eutamène, H.; Turrin, C.-O.; Théodorou, V.; Majoral, J.-P.; Caminade, A.-M.; Prandi, J.; Nigou, J.; Puzo, G. Mannodendrimers prevent acute lung inflammation by inhibiting neutrophil recruitment. *Proc. Natl. Acad. Sci. U.S.A.* **2013**, *110* (22), 8795–8800.
- (140) Posadas, I.; Romero-Castillo, L.; El Brahmī, N.; Manzaneres, D.; Mignani, S.; Majoral, J.-P.; Ceña, V. Neutral high-generation phosphorus dendrimers inhibit macrophage-mediated inflammatory response in vitro and in vivo. *Proc. Natl. Acad. Sci. U S A* **2017**, *114* (37), No. E7660-E7669.

- (141) Chauhan, A. S.; Diwan, P. V.; Jain, N. K.; Tomalia, D. A. Unexpected in vivo anti-inflammatory activity observed for simple, surface functionalized poly (amidoamine) dendrimers. *Biomacromolecules* **2009**, *10* (5), 1195–1202.
- (142) Ma, J. S.; Kim, W. J.; Kim, J. J.; Kim, T. J.; Ye, S. K.; Song, M. D.; Kang, H.; Kim, D. W.; Moon, W. K.; Lee, K. H. Gold nanoparticles attenuate LPS-induced NO production through the inhibition of NF- $\kappa$ B and IFN- $\beta$ /STAT1 pathways in RAW264. 7 cells. *Nitric Oxide* **2010**, *23* (3), 214–219.
- (143) Khan, M. A.; Khan, M. J. Nano-gold displayed anti-inflammatory property via NF- $\kappa$ B pathways by suppressing COX-2 activity. *Artif. Cells Nanomed. Biotechnol.* **2018**, *46* (sup1), 1149–1158.
- (144) Kumawat, M.; Madhyastha, H.; Umapathi, A.; Singh, M.; Revaprasadu, N.; Daima, H. K. Surface engineered peroxidase-mimicking gold nanoparticles to subside cell inflammation. *Langmuir* **2022**, *38* (5), 1877–1887.
- (145) Taketoshi, A.; Haruta, M. Size-and structure-specificity in catalysis by gold clusters. *Chem. Lett.* **2014**, *43* (4), 380–387.
- (146) Menchón, C.; Martín, R.; Apostolova, N.; Victor, V. M.; Álvaro, M.; Herance, J. R.; García, H. Gold nanoparticles supported on nanoparticulate ceria as a powerful agent against intracellular oxidative stress. *Small* **2012**, *8* (12), 1895–1903.
- (147) Fehaid, A.; Fujii, R.; Sato, T.; Taniguchi, A. Silver nanoparticles affect the inflammatory response in a lung epithelial cell line. *Open Biotechnol. J.* **2020**, *14* (1), 113.
- (148) Kumawat, M.; Madhyastha, H.; Singh, M.; Jain, D.; Daima, H. K. Functional silver nanozymes regulate cell inflammatory cytokines expression in mouse macrophages. *Colloids Surf. A Physicochem.* **2022**, *650*, 129294.
- (149) Agarwal, H.; Nakara, A.; Shanmugam, V. K. Anti-inflammatory mechanism of various metal and metal oxide nanoparticles synthesized using plant extracts: A review. *Biomed. Pharmacother.* **2019**, *109*, 2561–2572.
- (150) Soltani, R.; Guo, S.; Bianco, A.; Ménard-Moyon, C. Carbon nanomaterials applied for the treatment of inflammatory diseases: preclinical evidence. *Adv. Ther.* **2020**, *3* (9), 2000051.
- (151) Xu, X.; Zhang, K.; Zhao, L.; Li, C.; Bu, W.; Shen, Y.; Gu, Z.; Chang, B.; Zheng, C.; Lin, C.; Sun, H.; Yang, B. Aspirin-based carbon dots, a good biocompatibility of material applied for bioimaging and anti-inflammation. *ACS Appl. Mater. Interfaces* **2016**, *8* (48), 32706–32716.
- (152) Wu, Y.-S.; Ngai, S.-C.; Goh, B.-H.; Chan, K.-G.; Lee, L.-H.; Chuah, L.-H. J. F. i. p. Anticancer activities of surfactin and potential application of nanotechnology assisted surfactin delivery. *Front. Pharmacol.* **2017**, *8*, 761.
- (153) D'aiuto, F.; Nibali, L.; Parkar, M.; Patel, K.; Suvan, J.; Donos, N. Oxidative stress, systemic inflammation, and severe periodontitis. *J. Dent. Res.* **2010**, *89* (11), 1241–1246.
- (154) Johnson, A.; Kong, F.; Miao, S.; Thomas, S.; Ansar, S.; Kong, Z.-L. In-vitro antibacterial and anti-inflammatory effects of surfactin-loaded nanoparticles for periodontitis treatment. *Nanomaterials* **2021**, *11* (2), 356.
- (155) Friedman, A. J.; Phan, J.; Schairer, D. O.; Champer, J.; Qin, M.; Pirouz, A.; Blecher-Paz, K.; Oren, A.; Liu, P. T.; Modlin, R. L.; Kim, J. Antimicrobial and anti-inflammatory activity of chitosan-alginate nanoparticles: a targeted therapy for cutaneous pathogens. *J. Invest. Med.* **2013**, *133* (5), 1231–1239.
- (156) Haitao, Y.; Yifan, C.; Mingchao, S.; Shuaijuan, H. J. F. i. A novel polymeric nanohybrid antimicrobial engineered by antimicrobial peptide MccJ25 and chitosan nanoparticles exerts strong antibacterial and anti-inflammatory activities. *Front. Immunol.* **2022**, *12*, 5955.
- (157) Hu, C.-M. J.; Zhang, L.; Aryal, S.; Cheung, C.; Fang, R. H.; Zhang, L. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. *Proc. Natl. Acad. Sci. U S A* **2011**, *108* (27), 10980–10985.
- (158) Fang, R. H.; Hu, C.-M. J.; Luk, B. T.; Gao, W.; Copp, J. A.; Tai, Y.; O'Connor, D. E.; Zhang, L. Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery. *Nano Lett.* **2014**, *14* (4), 2181–2188.
- (159) Dehaini, D.; Fang, R. H.; Zhang, L. Biomimetic strategies for targeted nanoparticle delivery. *Bioeng. transl. med.* **2016**, *1* (1), 30–46.
- (160) Park, J. H.; Jiang, Y.; Zhou, J.; Gong, H.; Mohapatra, A.; Heo, J.; Gao, W.; Fang, R. H.; Zhang, L. Genetically engineered cell membrane-coated nanoparticles for targeted delivery of dexamethasone to inflamed lungs. *Sci. Adv.* **2021**, *7* (25), No. eabf7820.
- (161) Perlstein, R. S.; Whitnall, M. H.; Abrams, J. S.; Mougey, E. H.; Neta, R. Synergistic roles of interleukin-6, interleukin-1, and tumor necrosis factor in the adrenocorticotropin response to bacterial lipopolysaccharide in vivo. *Endocrinology* **1993**, *132* (3), 946–952.
- (162) Meager, A. Cytokine regulation of cellular adhesion molecule expression in inflammation. *Cytokine Growth Factor Rev.* **1999**, *10* (1), 27–39.
- (163) Kelly, M.; Hwang, J. M.; Kubes, P. Modulating leukocyte recruitment in inflammation. *J. Allergy Clin. Immunol.* **2007**, *120* (1), 3–10.
- (164) González-García, L. E.; MacGregor, M. N.; Visalakshan, R. M.; Lazarian, A.; Cavallaro, A. A.; Morsbach, S.; Mierczynska-Vasilev, A.; Mailänder, V.; Landfester, K.; Vasilev, K. Nanoparticles Surface Chemistry Influence on Protein Corona Composition and Inflammatory Responses. *Nanomaterials* **2022**, *12* (4), 682.
- (165) Moulari, B.; Béduneau, A.; Pellequer, Y.; Lamprecht, A. Lectin-decorated nanoparticles enhance binding to the inflamed tissue in experimental colitis. *J. Controlled Release* **2014**, *188*, 9–17.
- (166) Sinhmar, G. K.; Shah, N. N.; Rawal, S. U.; Chokshi, N. V.; Khatri, H. N.; Patel, B. M.; Patel, M. M. Surface engineered lipid nanoparticle-mediated site-specific drug delivery system for the treatment of inflammatory bowel disease. *Artif. Cells Nanomed. Biotechnol.* **2018**, *46* (sup2), 565–578.
- (167) Kedziorok, D. A.; Muja, N.; Walczak, P.; Ruiz-Cabello, J.; Gilad, A. A.; Jie, C. C.; Bulte, J. W. Gene expression profiling reveals early cellular responses to intracellular magnetic labeling with superparamagnetic iron oxide nanoparticles. *Magn. Reson. Med.* **2010**, *63* (4), 1031–1043.
- (168) Poirier, M.; Simard, J. C.; Antoine, F.; Girard, D. Interaction between silver nanoparticles of 20 nm (AgNP20) and human neutrophils: induction of apoptosis and inhibition of de novo protein synthesis by AgNP20 aggregates. *J. Appl. Toxicol.* **2014**, *34* (4), 404–412.
- (169) Ishihara, T.; Izumo, N.; Higaki, M.; Shimada, E.; Hagi, T.; Mine, L.; Ogawa, Y.; Mizushima, Y. Role of zinc in formulation of PLGA/PLA nanoparticles encapsulating betamethasone phosphate and its release profile. *J. Contr. Relea.* **2005**, *105* (1–2), 68–76.
- (170) Ishihara, T.; Kubota, T.; Choi, T.; Higaki, M. Treatment of experimental arthritis with stealth-type polymeric nanoparticles encapsulating betamethasone phosphate. *J. Pharmacol. Exp. Ther.* **2009**, *329* (2), 412–417.
- (171) Freise, C. E.; Liu, T.; Hong, K.; Osorio, R. W.; Papahadjopoulos, D.; Ferrell, L.; Ascher, N. L.; Roberts, J. P. The increased efficacy and decreased nephrotoxicity of a cyclosporine liposome. *Transplantation* **1994**, *57* (6), 928–932.
- (172) Gref, R.; Quéllec, P.; Sanchez, A.; Calvo, P.; Dellacherie, E.; Alonso, M. J. Development and characterization of CyA-loaded poly (lactic acid)-poly (ethylene glycol) PEG micro-and nanoparticles. Comparison with conventional PLA particulate carriers. *Eur. J. Pharm. Biopharm.* **2001**, *51* (2), 111–118.
- (173) Zhang, R.; He, R.; Qian, J.; Guo, J.; Xue, K.; Yuan, Y.-f. Treatment of experimental autoimmune uveoretinitis with intravitreal injection of tacrolimus (FK506) encapsulated in liposomes. *Invest. Ophthalmol. Vis. Sci.* **2010**, *51* (7), 3575–3582.
- (174) Yavuz, M. S.; Cheng, Y.; Chen, J.; Cobley, C. M.; Zhang, Q.; Rycenga, M.; Xie, J.; Kim, C.; Song, K. H.; Schwartz, A. G.; Wang, L. V.; Xia, Y. Gold nanocages covered by smart polymers for controlled release with near-infrared light. *Nat. Mater.* **2009**, *8* (12), 935–939.
- (175) Attarde, S. S.; Pandit, S. V. Anticancer potential of nanogold conjugated toxin GNP-NN-32 from Naja naja venom. *J. Venom. Anim. Toxins Incl. Trop. Dis.* **2020**, *26*, e20190047.

- (176) Martin, A. L.; Bernas, L. M.; Rutt, B. K.; Foster, P. J.; Gillies, E. R. Enhanced cell uptake of superparamagnetic iron oxide nanoparticles functionalized with dendritic guanidines. *Bioconjugate Chem.* **2008**, *19* (12), 2375–2384.
- (177) Sharonova, A.; Surmeneva, M.; Loza, K.; Prymak, O.; Epple, M.; Surmenev, R. Surface functionalization of titanium with silver nanoparticles. *J. Phys.: Conf. Ser.* **2019**, *1145*, 012032.
- (178) Cao, Z.; Kim, D.; Hong, D.; Yu, Y.; Xu, J.; Lin, S.; Wen, X.; Nichols, E. M.; Jeong, K.; Reimer, J. A.; Yang, P.; Chang, C. J. A molecular surface functionalization approach to tuning nanoparticle electrocatalysts for carbon dioxide reduction. *J. Am. Chem. Soc.* **2016**, *138* (26), 8120–8125.
- (179) Mout, R.; Moyano, D. F.; Rana, S.; Rotello, V. M. Surface functionalization of nanoparticles for nanomedicine. *Chem. Soc. Rev.* **2012**, *41* (7), 2539–2544.
- (180) Daima, H. K.; Selvakanan, P.; Shukla, R.; Bhargava, S. K.; Bansal, V. Fine-tuning the antimicrobial profile of biocompatible gold nanoparticles by sequential surface functionalization using polyoxometalates and lysine. *PLoS one* **2013**, *8* (10), No. e79676.
- (181) Torney, F.; Trewyn, B. G.; Lin, V. S.-Y.; Wang, K. Mesoporous silica nanoparticles deliver DNA and chemicals into plants. *Nanotechnol.* **2007**, *2* (5), 295–300.
- (182) Jung, H.-H.; Kim, S.-H.; Moon, J.-H.; Jeong, S.-U.; Jang, S.; Park, C.-S.; Lee, C.-K. Polymeric nanoparticles containing both antigen and vitamin D3 induce antigen-specific immune suppression. *Immune Netw.* **2019**, *19* (3), e19.
- (183) Yamashita, K.; Sakai, M.; Takemoto, N.; Tsukimoto, M.; Uchida, K.; Yajima, H.; Oshio, S.; Takeda, K.; Kojima, S. Attenuation of delayed-type hypersensitivity by fullerene treatment. *Toxicol.* **2009**, *261* (1–2), 19–24.
- (184) Siraganian, R. P.; Zhang, J.; Suzuki, K.; Sada, K. Protein tyrosine kinase Syk in mast cell signaling. *Mol. Immunol.* **2002**, *38* (16–18), 1229–1233.
- (185) Ryan, J. J.; Bateman, H. R.; Stover, A.; Gomez, G.; Norton, S. K.; Zhao, W.; Schwartz, L. B.; Lenk, R.; Kepley, C. L. Fullerene nanomaterials inhibit the allergic response. *J. Immunol.* **2007**, *179* (1), 665–672.
- (186) Hirst, S. M.; Karakoti, A. S.; Tyler, R. D.; Sriranganathan, N.; Seal, S.; Reilly, C. M. Anti-inflammatory properties of cerium oxide nanoparticles. *Small* **2009**, *5* (24), 2848–2856.
- (187) Colon, J.; Hsieh, N.; Ferguson, A.; Kupelian, P.; Seal, S.; Jenkins, D. W.; Baker, C. H. Cerium oxide nanoparticles protect gastrointestinal epithelium from radiation-induced damage by reduction of reactive oxygen species and upregulation of superoxide dismutase 2. *Nanomedicine: NBM* **2010**, *6* (5), 698–705.
- (188) Lee, S. S.; Song, W.; Cho, M.; Puppala, H. L.; Nguyen, P.; Zhu, H.; Segatori, L.; Colvin, V. L. Antioxidant properties of cerium oxide nanocrystals as a function of nanocrystal diameter and surface coating. *ACS Nano* **2013**, *7* (11), 9693–9703.
- (189) Wu, H.-Y.; Chung, M.-C.; Wang, C.-C.; Huang, C.-H.; Liang, H.-J.; Jan, T.-R. Iron oxide nanoparticles suppress the production of IL-1 $\beta$  via the secretory lysosomal pathway in murine microglial cells. *Part. Fibre Toxicol.* **2013**, *10* (1), 1–11.
- (190) Blank, F.; Gerber, P.; Rothen-Rutishauser, B.; Sakulku, U.; Salaklang, J.; De Peyer, K.; Gehr, P.; Nicod, L. P.; Hofmann, H.; Geiser, T.; Petri-Fink, A.; Von Garnier, C. Biomedical nanoparticles modulate specific CD4 $^{+}$  T cell stimulation by inhibition of antigen processing in dendritic cells. *Nanotoxicology* **2011**, *5* (4), 606–621.
- (191) Ko, W.-C.; Wang, S.-J.; Hsiao, C.-Y.; Hung, C.-T.; Hsu, Y.-J.; Chang, D.-C.; Hung, C.-F. Pharmacological role of functionalized gold nanoparticles in disease applications. *Molecules* **2022**, *27* (5), 1551.
- (192) Sumbayev, V. V.; Yasinska, I. M.; Garcia, C. P.; Gilliland, D.; Lall, G. S.; Gibbs, B. F.; Bonsall, D. R.; Varani, L.; Rossi, F.; Calzolari, L. Gold nanoparticles downregulate interleukin-1 $\beta$ -induced pro-inflammatory responses. *Small* **2013**, *9* (3), 472–477.
- (193) Moon, E.-Y.; Yi, G.-H.; Kang, J.-S.; Lim, J.-S.; Kim, H.-M.; Pyo, S. An increase in mouse tumor growth by an in vivo immunomodulating effect of titanium dioxide nanoparticles. *J. Immunotoxicol.* **2011**, *8* (1), 56–67.
- (194) Hardy, C. L.; LeMasurier, J. S.; Belz, G. T.; Scalzo-Inguanti, K.; Yao, J.; Xiang, S. D.; Kanellakis, P.; Bobik, A.; Strickland, D. H.; Rolland, J. M.; O’Hehir, R. E.; Plebanski, M. Inert 50-nm polystyrene nanoparticles that modify pulmonary dendritic cell function and inhibit allergic airway inflammation. *J. Immunol.* **2012**, *188* (3), 1431–1441.
- (195) Getts, D. R.; Martin, A. J.; McCarthy, D. P.; Terry, R. L.; Hunter, Z. N.; Yap, W. T.; Getts, M. T.; Pleiss, M.; Luo, X.; King, N. J.; Shea, L. D.; Miller, S. D. Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis. *Nat. Biotechnol.* **2012**, *30* (12), 1217–1224.
- (196) Frick, S. U.; Bacher, N.; Baier, G.; Mailänder, V.; Landfester, K.; Steinbrink, K. Functionalized polystyrene nanoparticles trigger human dendritic cell maturation resulting in enhanced CD4 $^{+}$  T cell activation. *Macromol. Biosci.* **2012**, *12* (12), 1637–1647.
- (197) Boridy, S.; Soliman, G. M.; Maysinger, D. Modulation of inflammatory signaling and cytokine release from microglia by celastrol incorporated into dendrimer nanocarriers. *Nanomed.* **2012**, *7* (8), 1149–1165.
- (198) Shaunak, S.; Thomas, S.; Gianasi, E.; Godwin, A.; Jones, E.; Teo, I.; Mireskandari, K.; Luthert, P.; Duncan, R.; Patterson, S.; Khaw, P.; Brocchini, S. Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation. *Nat. Biotechnol.* **2004**, *22* (8), 977–984.
- (199) Allen, R. P.; Bolandparvaz, A.; Ma, J. A.; Manickam, V. A.; Lewis, J. S. engineering. Latent, Immunosuppressive Nature of Poly (lactic-co-glycolic acid) Microparticles. *ACS Biomater. Sci. Eng.* **2018**, *4* (3), 900–918.
- (200) Getts, D. R.; Terry, R. L.; Getts, M. T.; Deffrasnes, C.; Muller, M.; van Vreden, C.; Ashhurst, T. M.; Chami, B.; McCarthy, D.; Wu, H.; Ma, J.; Martin, A.; Shae, L. D.; Witting, P.; Kansas, G. S.; Kuhn, J.; Hafezi, W.; Campbell, I. L.; Reilly, D.; Say, J.; Brown, L.; White, M. Y.; Cordwell, S. J.; Chadban, S. J.; Thorp, E. B.; Bao, S.; Miller, S. D.; King, N. J. C. Therapeutic inflammatory monocyte modulation using immune-modifying microparticles. *Sci. Transl. Med.* **2014**, *6* (219), 219ra7–219ra7.
- (201) Liu, Y.; Hardie, J.; Zhang, X.; Rotello, V. M. Effects of engineered nanoparticles on the innate immune system. *Semin. Immunol.* **2017**, *34*, 25–32.
- (202) De Stefano, D.; Carnuccio, R.; Maiuri, M. C. Nanomaterials toxicity and cell death modalities. *J. Drug Delivery* **2012**, *2012*, 1.
- (203) Akhtar, M. J.; Ahamed, M.; Kumar, S.; Khan, M. M.; Ahmad, J.; Alrokayan, S. A. Zinc oxide nanoparticles selectively induce apoptosis in human cancer cells through reactive oxygen species. *Int. J. Nanomedicine* **2012**, *7*, 845–857.
- (204) Yarosz, E. L.; Chang, C.-H. The role of reactive oxygen species in regulating T cell-mediated immunity and disease. *Immune Netw.* **2018**, *18* (1), e14.
- (205) Naik, E.; Dixit, V. M. Mitochondrial reactive oxygen species drive proinflammatory cytokine production. *J. Exp. Med.* **2011**, *208* (3), 417–420.
- (206) Bryan, N.; Ashwin, H.; Smart, N.; Bayon, Y.; Scarborough, N.; Hunt, J. A. The innate oxygen dependant immune pathway as a sensitive parameter to predict the performance of biological graft materials. *Biomater.* **2012**, *33* (27), 6380–6392.
- (207) Patel, G.; Patra, C.; Srinivas, S.; Kumawat, M.; Navya, P.; Daima, H. K. Methods to evaluate the toxicity of engineered nanomaterials for biomedical applications: A review. *Environ. Chem. Lett.* **2021**, *19*, 4253–4274.
- (208) Singh, R.; Sharma, A.; Saji, J.; Umaphathi, A.; Kumar, S.; Daima, H. K. Smart nanomaterials for cancer diagnosis and treatment. *Nano Conver.* **2022**, *9* (1), 21.
- (209) Umaphathi, A.; Madhyastha, H.; Navya, P.; Singh, M.; Madhyastha, R.; Daima, H. K. Surface chemistry driven selective anticancer potential of functional silver nanoparticles toward lung cancer cells. *Colloids Surf. A Physicochem. Eng. Asp.* **2022**, *652*, 129809.

- (210) Yazdimamaghani, M.; Moos, P. J.; Ghandehari, H. Global gene expression analysis of macrophage response induced by nonporous and porous silica nanoparticles. *Nanomedicine: NBM* **2018**, *14* (2), 533–545.
- (211) Almansour, M.; Alarifi, S.; Jarrar, B. J. I. j. o. n. In vivo investigation on the chronic hepatotoxicity induced by intraperitoneal administration of 10-nm silicon dioxide nanoparticles. *Int. J. Nanomed.* **2018**, *13*, 2685.
- (212) Tulinska, J.; Mikusova, M. L.; Liskova, A.; Busova, M.; Masanova, V.; Uhnakova, I.; Rollerova, E.; Alacova, R.; Krivosikova, Z.; Wsolova, L.; Dusinska, M.; Horvathova, M.; Szabova, M.; Lukan, N.; Stuchlikova, M.; Kuba, D.; Vecera, Z.; Coufalik, P.; Krumal, K.; Alexa, L.; Vrlikova, L.; Buchtova, M.; Dumkova, J.; Piler, P.; Thon, V.; Mikuska, P. Copper oxide nanoparticles stimulate the immune response and decrease antioxidant defense in mice after six-week inhalation. *Front. Immunol.* **2022**, *13*, 874253.
- (213) Johnson, B. M.; Fraietta, J. A.; Gracias, D. T.; Hope, J. L.; Stairiker, C. J.; Patel, P. R.; Mueller, Y. M.; McHugh, M. D.; Jablonowski, L. J.; Wheatley, M. A.; Katsikis, P. D. Acute exposure to ZnO nanoparticles induces autophagic immune cell death. *Nanotoxicology* **2015**, *9* (6), 737–748.
- (214) Hong, H.; Liu, Z.; Li, S.; Wu, D.; Jiang, L.; Li, P.; Wu, Z.; Xu, J.; Jiang, A.; Zhang, Y.; Wei, Z.; Yang, Z. Zinc oxide nanoparticles (ZnO-NPs) exhibit immune toxicity to crucian carp (*Carassius carassius*) by neutrophil extracellular traps (NETs) release and oxidative stress. *Fish Shellfish Immunol.* **2022**, *129*, 22–29.
- (215) Hong, F.; Zhou, Y.; Zhou, Y.; Wang, L. Immunotoxic effects of thymus in mice following exposure to nanoparticulate TiO<sub>2</sub>. *Environ. Toxicol.* **2017**, *32* (10), 2234–2243.
- (216) Turabekova, M.; Rasulev, B.; Theodore, M.; Jackman, J.; Leszczynska, D.; Leszczynski, J. Immunotoxicity of nanoparticles: A computational study suggests that CNTs and C 60 fullerenes might be recognized as pathogens by Toll-like receptors. *Nanoscale* **2014**, *6* (7), 3488–3495.
- (217) Sayers, B. C.; Germolec, D. R.; Walker, N. J.; Shipkowski, K. A.; Stout, M. D.; Cesta, M. F.; Roycroft, J. H.; White, K. L.; Baker, G. L.; Dill, J. A.; Smith, M. J. Respiratory toxicity and immunotoxicity evaluations of microparticle and nanoparticle C60 fullerene aggregates in mice and rats following nose-only inhalation for 13 weeks. *Nanotoxicology* **2016**, *10* (10), 1458–1468.
- (218) Malachowski, T.; Hassel, A. J. E. R. Engineering nanoparticles to overcome immunological barriers for enhanced drug delivery. *Eng. Regn.* **2020**, *1*, 35–50.
- (219) Singh, R.; Karakoti, A. S.; Self, W.; Seal, S.; Singh, S. Redox-Sensitive Cerium Oxide Nanoparticles Protect Human Keratinocytes from Oxidative Stress Induced by Glutathione Depletion. *Langmuir* **2016**, *32* (46), 12202–12211.
- (220) Shi, L.; Zhang, J.; Zhao, M.; Tang, S.; Cheng, X.; Zhang, W.; Li, W.; Liu, X.; Peng, H.; Wang, Q. Effects of polyethylene glycol on the surface of nanoparticles for targeted drug delivery. *Nanoscale* **2021**, *13* (24), 10748–10764.
- (221) Hanley, C.; Thurber, A.; Hanna, C.; Punnoose, A.; Zhang, J.; Wingett, D. G. J. N. r. l. The influences of cell type and ZnO nanoparticle size on immune cell cytotoxicity and cytokine induction. *Nanoscale Res. Lett.* **2009**, *4* (12), 1409–1420.
- (222) Kickhoefer, V. A.; Garcia, Y.; Mkyas, Y.; Johansson, E.; Zhou, J. C.; Raval-Fernandes, S.; Minoofar, P.; Zink, J. I.; Dunn, B.; Stewart, P. L.; Rome, L. H. Engineering of vault nanocapsules with enzymatic and fluorescent properties. *Proc. Natl. Acad. Sci. U S A* **2005**, *102* (12), 4348–4352.
- (223) Syn, N. L.; Wang, L.; Chow, E. K.-H.; Lim, C. T.; Goh, B.-C. J. T. i. b. Exosomes in cancer nanomedicine and immunotherapy: prospects and challenges. *Trends Biotechnol.* **2017**, *35* (7), 665–676.